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Tuberculosis is a contagious disease caused by Mycobacterium Tuberculosis and is 
recognised as a global public health emergency.  New approaches are required to 
improve the chemotherapy of TB, in particular to target the reservoir of M. 
Tuberculosis that accumulates in alveolar macrophages and lung lesions.  The aim 
of this thesis was to develop polymeric nanoparticle-loaded formulations for the 
delivery of rifampicin to the lungs.  Poly (vinyl alcohol) nanospheres (NS) and 
nanocapsules (NC) were developed using a modified nanoprecipitation method.  
Both types of nanocarrier were spherical with a mean diameter of ca. 220 nm (NS) 
and 150 nm (NC).  Rifampicin was successfully encapsulated with efficiencies of 
29.3 ± 0.7% and 32.3 ± 0.3%, for NS and NCs, respectively.  Methods for enhancing 
the stability and modifying the release of rifampicin were developed.  The uptake of 
the PVA nanocarriers was studied in-vitro using the J774A.1 macrophage-like cell 
line.   After 6 h incubation, the amount of rifampicin imported into macrophages by 
drug-loaded nanoparticles, containing 1000 µg/ml of drug, was twice (NC) or three 
times (NS) greater than that attained with rifampicin solution.  The drug-loaded PVA 
nanoparticles were formulated into a powder for pulmonary administration by spray 
drying into lactose to yield spherical microspheres of ca. 2 µm diameter.  The 
deposition studies of the spray dried powders, carried out using a modified twin 
stage impinger, showed that the NS-loaded-microspheres had a better deposition 
profile than the NC-loaded microspheres.  This work generated novel PVA 
nanocarriers, demonstrated that they are effective in targeting rifampicin to 
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Tuberculosis (TB), a highly contagious chronic granulomatous bacterial infection, is 
the second leading cause of death from an infectious disease worldwide after HIV.  
TB is caused by the inhalation of Mycobacterium tuberculosis and was declared as 
global emergency in 1993.  In 2010, there were an estimated 8.8 million people who 
developed the active disease and 1.5 million people who died from TB (WHO, 2011).   
 
Mycobacterium tuberculosis has a complex cell wall, composed of long-chain fatty 
acids, glycolipids, peptidoglycan, and proteins, and a slow doubling time (18 – 24 h). 
It is primarily a respiratory pathogen, and usually transmitted by the cough of a 
person with active disease (Kumar and Robbins, 2007).  Primary TB occurs within 
the first year or so after exposure, and is the result of an uncontrolled initial infection.  
The majority (90 %) of infected humans effectively contain, but do not completely 
eradicate the bacteria, and are defined as having “latent” infection (Kumar and 
Robbins, 2007; Selwyn et al., 1989). This is a clinical term, meaning a person is 
infected but is asymptomatic and not contagious.  It is great concern that TB persists 
as a latent infection in an estimated one third of the world population (2 billion 
people), providing a reservoir of potential disease and contagion.  Risk of developing 
active disease varies according time since exposure, age and host immunity.  The 
lifetime risk of infection activation for a latently infected human has been estimated to 
be 2-23 % (Parish et al., 1998). Schematic representation of the progression of TB is 














The pathological and inflammatory processes in active TB produce symptoms such 
as loss of appetite, weakness, fever, weight loss, night sweat, chest pain, respiratory 
insufficiency, and cough (Bloom and Murray, 1992).  The old name for TB was 
“consumption” as this disease is developed at a leisurely pace and with multiple 
symptoms which lead to gradual debilitation and physical exhaustion.  If untreated, 
the wasting and weight loss may be very severe, leading to death.  Mortality rates of 
TB range from 50 to 80% in untreated smear-positive individuals to 30% with 
inconsistent control programmes and drop to lower than 5% when directly observed 
therapy (DOT) and active TB control programmes are instituted (Singh, 2004, 
Onyebujoh et al., 2006).   
TB appears to be under control in developed countries but starkly manifest in places 
like south eastern Asia and Africa, where 84 % of the estimated new cases in 2010 
occurred.  This is mostly due to complications of HIV infection and drug resistance 
(Brennan, 1997).  Currently, multidrug-resistant (MDR) TB has a high incidence, in 
an increasing order.  In 2010, there were an estimated 650 000 cases of MDR-TB 
among the world’s 12.0 million prevalent cases of TB (WHO, 2011).  It is estimated 
that 1 billion more people will be infected, 200 million will develop the disease, and 
70 million will die in case surveillance and control strategies continue as they are 
(WHO, 2011). 
 
1.1.2. Primary tuberculosis 
Once inhaled, most M. tuberculosis organisms will settle in the upper respiratory 
epithelium, where they are likely to be expelled by the mucociliary escalator (Nardell, 





macrophages and either killed or else survive to initiate an infection (Dannenberg, 
1993; Schlesinger, 1996).  The fate of the bacillus within the infected cell depends on 
the type and activation state of cell found. It is believed that a bacillus is able to 
survive within a macrophage if the phenotype of the phagocytic cell interacting with 
M. tuberculosis displays an anti-inflammatory phenotype also known as “alternative 
activation state”.  These cells have increased expression of pattern recognition 
receptors such as the mannose and scavenger receptors facilitating cell and bacillus 
interaction but they also have a reduced oxidative burst and they are unable to 
eliminate the bacillus (Schlesinger, 1996).  Once inside the phagocyte, the 
mycobacteria modulate the behaviour of its phagosome by preventing its fusion with 
acidic, hydrolytically-active lysosomes (Rohde et al., 2007; Sturgill-Koszycki et al., 
1994). 
Over the next 2 to 3 weeks, surviving organisms multiply, kill their host macrophages 
and release more bacilli infecting additional host cells.  Pulmonary inflammation due 
to interaction of bacillus with macrophages and other cells results in recruitment of 
monocytes, neutrophils, and primed T cells and B cells to lungs, culminating in 
formation of granulomatous lesions (Figure 1.2).   
Granuloma formation is the classic pathologic feature of TB, and serves as an 
effective means for containing pathogens, preventing their continued growth and 
dissemination.   In its early stage, the granuloma has a core of infected macrophages 
enclosed by foamy macrophages and other mononuclear phagocytes, surrounded by 
lymphocytes. This tissue response contains the infection and spells the end of the 
period of rapid replication for the mycobacteria. As the granuloma matures it 





excludes the majority of lymphocytes from the centre of the structure. Concomitant 
with this transition is a marked reduction in the number of blood vessels penetrating 
the granuloma. At this stage there is a noticeable increase in the number of foamy 
macrophages responsible for the accumulation of caseous debris in the centre of the 
granuloma, which portends progression to active disease.  Although M. tuberculosis 
bacilli are unable to multiply within this caseous tissue, due to its acidic pH, low 
availability of oxygen, and the presence of toxic fatty acids, some organisms may 
remain dormant there for decades.  
The strength of the host’s cell mediated immunity (CMI) determines whether an 
infection is arrested here or progresses to the next stages.  With good CMI, the 
infection may be arrested permanently at this point. The granulomas subsequently 
heal, leaving small fibrous and calcified lesions. However, if CMI is insufficient, 
macrophages containing ingested but viable M. tuberculosis organisms may escape 
from the granuloma via the intrapulmonary lymphatic channels. This results in the 
rapid spread of the infection to the regional hilar lymph nodes. As disease 
progresses further, the semisolid caseous, necrotic centre of the granuloma liquefies 
and cavitates spilling thousands of infectious virulent bacilli into the airways. This 
damage to the lungs triggers development of a productive cough facilitating 
generation of the infectious aerosol and completion of the bacterium's life cycle 
resulting in relatively large areas of necrotic debris, each surrounded by a layer of 
epithelioid histiocytes and multinucleated giant cells.  At this stage, effective 







1.1.3. Post-primary tuberculosis 
There are two routes to a repeat episode of TB (post-primary pulmonary TB): either 
by reactivation of a dormant primary lesion or by inhalation of additional M. 
tuberculosis organisms. In post-primary TB, infection proceeds in spite of existing 
immunity.   
M. tuberculosis bacilli can persist for decades in a dormant state inside a granuloma, 
particularly in the apical regions of the lung. Reactivation of these latent organisms 
can also lead to post-primary disease, even in persons who successfully fought their 
initial battle against TB. The mechanisms which govern dormancy and reactivation, 
within either the organism or the host, are not yet understood. The host typically 
mounts an inflammatory response to reactivation TB, with the lesion appearing 
circumscribed and necrotic. Reactivation TB that progresses to the cavitary stage 
favors the propagation of virulent and drug resistant strains, as the increased oxygen 
concentration allows multiplication of the organisms producing large numbers that 
are thought to be necessary for the evolution of drug resistance mutants (Nardell, 
1993). 
In recurrent exposure to M. tuberculosis, a hypersensitivity reaction is the 
characteristic response, accompanied by tissue necrosis and caseation.  
Lymphocytes and other cells converge upon the site and form a wall of fibrous tissue 
in an attempt to seal off the necrotic site (Spencer, 1985). Some lymphatic spread 
may occur, but in this case, the hilar lymph nodes are not implicated. Most often, 
caseated granulomas heal over time, shrinking as they become fibrotic and then 
calcified. However, if healing is impaired, the growing lesions may erode adjacent 





multiply freely, leading to huge numbers of bacilli (Nardell, 1993). An open cavitated 
lesion can leak infectious material directly into the bronchus, resulting in the 
continuous discharge of bacilli into the sputum (Spencer, 1985). Leaked M. 
tuberculosis bacilli can also be inhaled into other portions of the host’s lungs, 
resulting in tuberculous bronchopneumonia.  If the growing granulomatous lesion 
erodes the wall of a vein, organisms can spread in the circulating blood, resulting in 








Figure1.2. Histological progression of the human tuberculosis granuloma (adapted 








1.1.4. Drug treatment of TB 
Since the control measures for TB such as Bacillus Calmette-Guerin (BCG) 
vaccination and chemoprophylaxis appear to be unsatisfactory, treatment with anti-
tubercular (anti-TB) drugs is the only option available.  The principal objective of 
chemotherapy in TB patients is the eradication of the whole bacillary load (Petrini 
and Hoffner, 1999).  Modern therapy relies on a combination of potent bactericidal 
agents, such as isoniazid, rifampicin, pyrazinamide and ethambutol in a treatment 
with six month duration. In some instances, there can be an initial resistance of the 
bacillus to isoniazid, making it necessary to add streptomycin to the treatment.  In 
the case of MDR-TB, in which the virulent bacilli is resistant to at least rifampicin and 
isoniazid (Telenti and Iseman, 2000), the treatment period is extended, and 
frequently relies on the use of more side effect-associated second-line drugs. 
First-line drugs are mainly bactericidal, and combine a high degree of efficacy with a 
relative low toxicity to the patient during treatment; these include isoniazid, 
rifampicin, streptomycin, ethambutol, and pyrazinamide.  Second-line drugs are 
mainly bacteriostatic, have a lower efficacy and are usually more toxic; these include 
para-aminosalicylic acid, ethionamide, and cycloserine among others (Cohn et al. 
1997). Effective TB chemotherapy must include early bactericidal action against 
rapidly growing organisms and subsequent sterilization of dormant populations of 
bacilli. 
The first-line drugs exhibit early bactericidal activity against actively metabolizing 
bacilli and the bacteriostatic second-line drugs are reserved for treatment in the 
advert of resistance. Among all first-line anti-TB agents, isoniazid has the greatest 





rifampicin, streptomycin. However, isoniazid frequently causes fever, and is one of 
the drugs with the highest degree of toxicity (Morehead, 2000). Although TB is a 
serious illness, it can be cured in most new cases as long as, once diagnosed, 
appropriate chemotherapy is employed. 
The treatment currently recommended by the WHO consists of the combined 
administration of isoniazid, rifampicin, pyrazinamide and streptomycin (or 
ethambutol) during the first 2 months, followed by the combination of isoniazid and 
rifampicin for at least 4 additional months (Table 1.1). This revolutionary treatment 
aims initially at a bacteriostatic action, inhibiting the synthesis of cell wall, nucleic 
acids and mycobacterial proteins (Figure 1.3), and, thereby, leading to a rapid 
elimination of most part of the infecting bacilli. The therapy also aims at a 
subsequent bactericidal action to consolidate the treatment through the elimination of 
















 Rifampicin (450-600 mg) 
 Isoniazid (300 mg) 
 Ethambutol  (15 mg/kg) 
 Pyrazinamide (1.5-2 g) 
 
 Rifampicin  (450-600 
mg) 

















WHO invested in universal treatment adherence programs, through a process 
currently known as the directly observed treatment short-course (DOTS), where 
health care workers counsel patients, perform progress surveillance, and make sure 
that each medication dose is correctly taken (NSB Editorial Comment, 2000).  DOTS 
strategy prevents the occurrence of new infections and, more importantly, makes 
MDR/XDR-TB generation impractible. However, TB continues to be a leading killer of 
humans worldwide (WHO, 2011).  The long treatment period and the associated side 
effects of the administered drugs lead to patient non-compliance, infection 





























1.2. Pulmonary drug delivery 
Local delivery of drugs to the lower respiratory tract by aerosol inhalation is highly 
desirable in patients with pulmonary diseases like asthma (Georgitis, 1999), chronic 
obstructive pulmonary disease (COPD) or cystic fibrosis (Touw et al., 1995).  This 
route of administration is characterised by the rapid response which is achieved by 
the delivery of the drug in close proximity to its intended site of action.  In addition, 
the inhaled route allows the local administration of smaller doses compared to 
delivery by the oral route, thereby reducing the potential incidence of adverse 
systemic effects and reducing drug costs (Guo et al. 2005).   
 
1.2.1. Structure and physiology of the airways 
The human respiratory system can be divided in two functional regions: the 
conducting airways and the respiratory region (Figure 1.4). The conducting airways, 
which are composed of the nasal cavity and associated sinuses, the pharynx, larynx, 
trachea, bronchi, and bronchioles, filter and condition the inspired air. From trachea 
to the periphery of the airway tree, the airways repeatedly branching dichotomously 
into two daughter branches with smaller diameters and shorter length than the 
parent branch (Weibel, 1991). For each new generation of airways, the number of 
branches is doubled and the cross sectional area is exponentially increased. The 
conducting region of the airways generally constitutes generation 0 (trachea) to 16 
(terminal bronchioles). The respiratory region, where gas exchange takes place, 
generally constitutes generation 17-23 and is composed of respiratory bronchioles, 





branches before the gas exchange area is reached can vary from as few as 6 to as 
many as 28-30 (Plopper, 1996). 
 
 
Figure 1.4.  The human respiratory tract (Lansley, 1993) 
 
The human airway epithelium consists of a pseudostratified layer composed of at 
least six distinct epithelial cell types: ciliated cells, mucous goblet cells, Clara cells, 
serous cells, basal cells, and granulated cells.  Cellular composition of the epithelium 
varies substantially at different levels of the lung between the trachea and the 





ciliated cells, which are the most abundant cell at all levels of the airways. In the 
higher airways, the ciliated cells are interspersed by secretory cells, mainly mucus-
secreting goblet cells. At lower levels the ciliated cells are interspersed mainly by 
Clara cells (Forbes, 2000).  Diagrammatic representations of the typical epithelium in 
the higher airways, at the bronchiolar level, and in the alveolar region are illustrated 
in Fig.1.5.  
 
Figure 1.5.  Comparison of the lung epithelium at different sites within the lungs 
(adapted from Patton and Byron, 2007). 
 
 
1.2.2. Particle deposition in the airways 
During inhalation, drug particles are transported into the airways within inspired air.  
A proportion of the particles travelling through the respiratory system will be trapped 
after coming into contact with the wet airspace surfaces, a phenomenon which is 





on particle properties (e.g. size, shape, density, and charge), respiratory tract 
morphology, and the breathing pattern (e.g. airflow rate and tidal volume) (Heyder et 
al., 2002). These parameters determine not only the quantity of particles that are 
deposited but also in what region of the respiratory tract the particles are deposited. 
As the cross-sectional area of the airways increases, the airflow rate rapidly 
decreases, and consequently the residence time of the particles in the lung 
increases from the large conducting airways towards the lung periphery (Schulz et 
al., 2000).  
The most important mechanisms of particle deposition in the respiratory tract are 
inertial impaction, sedimentation, and diffusion. Inertial impaction occurs 
predominantly in the extrathoracic airways and in the tracheobronchial tree, where 
the airflow velocity is high and rapid change in airflow direction occurs (Schulz et al., 
2000). The mass median aerodynamic diameter (MMAD) is considered to be the 
most important physical parameter influencing particle deposition in the lungs 
(Schulz et al., 2000).  Generally, particles with a diameter larger than 10 μm are 
most likely deposited in the extrathoracic region, whereas 2- to 10 μm particles are 
deposited in the tracheobronchial tree by inertial impaction (Schulz et al., 2000). A 
long residence time of the inspired air favours particle deposition by sedimentation 
and diffusion (Heyder et al., 2002).  Sedimentation is of greatest importance in the 
small airways and alveoli and is most pronounced for particles with a diameter of 
0.5-2 μm (Schulz et al., 2000). Sub-micron particles (<0.5 μm in diameter) are 
deposited mainly by diffusional transport in the small airways and lung parenchyma 





relationship between particle size and total respiratory tract deposition has been 














1.2.3. The fate of particles in the airway 
1.2.3.1. The mucociliary clearance 
The mucociliary clearance is one of the most important mechanical host defense in 
the lung. By the coordinated movements of cilia, mucus is swept out of the nasal 
cavity and lungs, respectively, towards the pharynx where it is swallowed. In the 
nose, clearance rates of 3-25 mm/min have been shown in normal subjects (Mygind 
et al., 1998). There is an inverse relationship between mucus velocity and airway 
generation, which relates to the lower percentage of ciliated cells, shorter cilia, lower 
ciliary beat frequency, and lower number of secretory cells in the peripheral airways. 
The thickness of the mucus layer varies along the conducting being about 8 μm in 
the trachea and about 2 μm in the bronchioles (Mercer et al., 1992). The mucus layer 
is continuous in the larger human bronchial airways, but consists of discontinuous 
rafts in the smaller bronchi and bronchioles (Mercer et al., 1992). The surface liquids 
of the ciliated airways are composed of two phases: an aqueous periciliary phase of 
epithelial lining fluid close to the cell surface in which the cilia beat, plus a gel phase 
of mucus on top of the aqueous phase. A phospholipid layer between the phases 
lowers the surface tension between them (Samet et al., 1994). Mucus is secreted 
primarily from the serous cells of submucosal glands and from goblet cells, and is 
composed of water (95%), glycoproteins (mucins) (2%), proteins (1%), inorganic 
salts (1%), and lipids (1%) (Samet et al., 1994). Regulation of the water content is of 








1.2.3.2. Alveolar clearance 
Alveolar macrophages are found on the alveolar surface. These phagocytic cells 
play important roles in the defense against inhaled bacteria and particles that reach 
the alveoli. Particles deposited in the lung parenchyma of rabbits and rats have been 
demonstrated to be phagocytized by alveolar macrophages within a few hours. The 
macrophages are cleared from the alveoli to the bronchioles by the lining fluid, and 
then from the airways by the mucociliary escalator (Jeffery, 1995). 
 
1.2.3.3. Enzymatic activity 
The lung presents lower enzymatic activity when compared to other mucosal 
surfaces, such as those found in the gastro-intestinal tract (Evora et al., 1998).  
However, some enzymes have already been identified including; protease inhibitors 
and isozymes of the cytochrome P450 family (Patton and Platz, 1992), which are 
most concentrated in clara cells, Type 2 cells and to a lesser extent in alveolar 
macrophages.  Lysozyme is a 14.5 kDa cationic enzyme which is synthesized and 
released by the human surface epithelial cells, as well as pulmonary alveolar 
macrophages (Duszyk, 2001). Other enzymes include esterases, peptidases, UDP-








1.3. Nanoparticle drug delivery systems 
1.3.1. Definition  
Nanoparticles are defined simply as solid, colloidal particles that vary in size from 10 
to 1000 nm (Sanjeeb et al., 2003).  A therapeutic agent may be dissolved, 
entrapped, adsorbed, attached or encapsulated into the nanoparticle matrix.  
Depending on their structure, nanoparticles can be further classified as either 
nanospheres (NS) or nanocapsules (NC) (Figure 1.7).  Nanospheres are matrix 
systems in which the therapeutic agent is physically and uniformly dispersed, 
whereas nanocapsules are vesicular systems in which the drug is confined to a 
cavity surrounded by a polymer membrane (Sanjeeb et al., 2003).  Nanoparticles 
can be made from biocompatible and biodegradable materials such as solid lipids or 
polymers which may be natural (e.g. gelatin) or synthetic (e.g. poly (lactide)) 
(Soppimath et al., 2001).  Liposomes, nanovesicular structures produced from 
natural phospholipids, are the most widely investigated delivery system for 
phagocyte-targeted therapies (Kelly et al., 2010).  However, it is beyond the scope of 
this review to describe these nanoparticulate systems and highlight their advantages 
and method of manufacture. 
High carrier capacity, high stability and the feasibility of incorporating both 
hydrophobic and hydrophilic drugs are among the important technological 
advantages of nanoparticles as drug carriers. In addition, it has been claimed that 
the clearance of drug-loaded nanoparticles from the lung can be minimized to 
enhance drug retention at topical sites (Schurch et al., 1990).  Such properties make 







(a)        (b) 
Figure 1.7. Schematic representation of the two classes of nanoparticles: (a) 
nanospheres (matrix systems in which the therapeutic agent is physically and 
uniformly dispersed), (b) nanocapsules (vesicular systems in which the drug is 
confined to a cavity surrounded by a unique polymer membrane) (Adapted from 




1.3.2. Manufacture of polymeric nanoparticles 
1.3.2.1. Emulsification-solvent evaporation 
The emulsification-solvent evaporation method was the first method used to prepare 
biodegradable and injectable lattices by Gurny et al. (1981).  Briefly, this method is 
carried out by dissolving the drug and polymer are in a volatile, water immiscible 
organic solvent such as dicholoromethane, chloroform or ethyl acetate. The 
emulsion is prepared by adding water and a surfactant to the polymer solution.  The 
nanosized polymeric droplets are induced using high energy homogenization or 
sonicator. The organic phase evaporation is achieved using a rotary evaporator or by 
continuous stirring and the nanoparticles are collected by centrifugation or 







1.3.2.2. Solvent displacement and interfacial deposition method 
One of the easiest and reproducible techniques for preparing nanoparticles is the 
solvent displacement (also called nanoprecipitation) method developed by Fessi et 
al. (1989) which has been widely used to prepare nanoparticles.  The method is 
based on the precipitation of preformed polymer following displacement of a semi-
polar solvent miscible with water in the presence or absence of surfactant. The basic 
principle of this technique is similar to spontaneous emulsification of the organic 
phase containing drug and polymer into the external aqueous phase. In brief, both 
the polymer and drug are dissolved in a water miscible organic solvent (polymer 
solvent phase) of intermediate polarity (e.g. acetone and ethanol). The resulting 
organic phase is injected into a stirred aqueous phase (non-solvent phase) 
containing a surfactant as stabilizer. The nanoparticles are formed instantaneously 
during the rapid diffusion of the organic phase into the aqueous phase.  Parameters 
affecting the physicochemical properties of the prepared nanoparticles include: 
miscibility of the organic solvent with the nonsolvent; nature of the polymer solvent 
interactions and concentration of the polymer in the organic phase. 
 
1.3.2.3. Emulsification–solvent diffusion 
The emulsification solvent diffusion or emulsification-solvent displacement method is 
the most widely used method for preparing nanoparticles due to several advantages. 
These include high drug entrapment efficiency for poorly water soluble drugs, narrow 
particle size distribution, high batch-to-batch reproducibility, no requirement for 
homogenization, simplicity, ease of scale up and rapid organic solvent extraction 





water soluble solvent.  The organic phase is saturated with water to ensure the initial 
thermodynamic equilibrium. It is then diluted with an extensive amount of pure water 
to facilitate diffusion of the organic solvent from the organic phase droplets leading to 
the precipitation of the polymer. The aqueous phase may contain surfactants while 
the organic phase sometimes contains an emulsifier. Finally, the solvent is 
eliminated by evaporation or filtration, depending upon the boiling point. Several 
parameters can affect the size of the nanoparticles such as miscibility of the water 
with the organic solvent, stirring rate, concentration of the surfactant(s) and 
concentration of the polymer is the organic phase. 
 
1.3.2.4. Salting out method 
The salting-out procedure can be considered as a modification of the 
emulsification/solvent diffusion method (Galindo-Rodriguez et al., 2004).  The 
separation of a water miscible solvent from aqueous solution is achieved via a 
salting-out effect.  Briefly, a water miscible organic solvent, usually acetone, 
containing polymer and drug is added drop wise to an aqueous phase saturated with 
an electrolyte or non-electrolyte (such as magnesium chloride, calcium chloride or 
sucrose) with a colloidal stabilizer (such as polyvinyl pyrrolidone) under agitation to 
form an o/w emulsion. A sufficient volume of water is added to enhance the diffusion 
of acetone to the water phase and NSs are thus obtained. The technique offers 
advantages such as the avoidance of chlorinated solvents and surfactants, 
minimization of stress, useful for heat-sensitive substances, high encapsulation 





washing steps required to achieve purity of the nanoparticles and the possibility of 
incompatibility between drugs and salts. 
 
1.3.2.5. Polymerization method 
In the polymerization method, monomers are polymerized to form nanoparticles in 
aqueous solution. The polymerization method can be classified into emulsion and 
interfacial polymerization. The emulsion polymerization method is the fastest and 
most scalable method of producing nanoparticles.  It can be classified into two 
categories; continuous organic phase or continuous aqueous phase methodology 
depending on the use of the continuous phase. In general, the monomer is dissolved 
into an organic or aqueous continuous phase. Additional monomer molecules are 
then emulsified into the emulsion droplets and stabilized by surfactant. The 
polymerization is started by chemical initiation, pH shift or by irradiation of gamma, 
ultraviolet or visible rays. In the continuous phase, chain growth starts when the 
initiated monomer ions or monomer radicals collide with each other to form 
aggregates which are stabilized by polymeric emulsifier particles.  
 
1.3.3. Anti-TB drugs encapsulation into nanoparticles 
The encapsulation of anti-TB drugs in nanocarriers has a number of advantages.  
These include improved stability of these drugs against degradation, minimized 
toxicity, improved bioavailability by reducing fluctuations in therapeutic ranges, 
controlled release and reduced dosing frequency, which may resolve the problem of 






Several studies reported the efficacy of anti-TB drug-loaded nanoparticles 
administered orally, subcutaneously or intravenously.  Pandey et al., (2003) 
administered poly (DL-lactide-co-glycolide) (PLG) nanoparticles encapsulated with 
three front-line anti-tubercular drugs subcutaneously to mice.  They showed that 
therapy with drug-loaded PLG nanoparticles resulted in undetectable bacterial 
counts in the lungs and spleen of infected mice. The particle preparation showed a 
better chemotherapeutic efficacy compared with a daily drug treatment. A similar 
study was performed by Johnson et al. (2005) in which treatment using nanoparticle 
encapsulated and non-encapsulated drugs significantly reduced the bacterial count 
and lung histopathology. However, the nanoparticle formulation was administered 
every 10 days and may lead to better patient compliance compared to 
nonencapsulated formulations. In another study Pandey et al. evaluated the 
efficiency of oral encapsulated ethambutol in combination with PLG nanoparticles 
loaded with rifampicin, isoniazid and pyrazinamide in a murine tuberculosis model.  
The study concluded that the combination of 4-drugs in a nanoprticluate formulation 
had the potential to shorten the duration of TB chemotherapy besides reducing the 
dosing frequency. 
These studies showed that that the delivery of anti-TB drugs incorporated in 
nanoparticles is a promising alternative to conventional oral drug delivery to achieve 
better patient compliance. The obtained results in the TB management using 
nanoparticles might be due to different effects. It is possible that the constant drug 
plasma levels are more effective than fluctuating drug plasma levels after oral 
administration of free drugs, or even that a small nanoparticle accumulation in the 





a controlled release of the therapeutic agent, this undetectable local drug targeting 
might be the key advantage considered by nanoparticle formulation. 
 
1.4. Pulmonary delivery of nanoparticles 
1.4.1. Local delivery of anti-TB drugs  
The lung is the primary, if not the sole, portal of entry for mycobacteria that cause 
TB.  In addition, more than 80 % of TB cases present exclusive pulmonary infection.  
High chemotherapeutic doses are required, but only a small fraction of the total dose 
reaches the lungs after oral administration. Even this small fraction is cleared in few 
hours explaining the need to administer anti-TB on a daily basis.  Clearly, the local 
delivery of these drugs via inhalation offers a number of advantages over the 
systemic route.  Exposing the mycobacteria in the lung to high drug concentrations 
maximises the chances of complete eradication of the virulent bacilli.   
Moreover, the lung mucosa represents a large surface from which drugs may be 
systemically absorbed into the bloodstream (Mathias et al., 2010). During the 
process of systemic absorption from the lungs, drugs introduced into this organ 
provide early and high concentrations within it. This is advantageous if, as in 
pulmonary TB, the lungs are the target site of drug delivery.  In addition, lung 
macrophages are efficient at fulfilling their role of phagocytosing material entering 
the lungs. It has long been established that particulate (Moller et al., 2001; Evora et 
al., 1998) or vesicular (Myers et al., 1993; Shephard et al., 1981) drug delivery 
systems introduced into the deep lung are likely to be taken up up by alveolar 





the site of infection, it has been argued that uptake of drug delivery systems by 
infected macrophages effects rescue of the macrophage from ‘alternative activation,’ 
(Kahnert et al., 2006) enabling the elaboration of innate bactericidal responses 
(Sharma et al., 2007). 
 
1.4.2. Method of delivering nanoparticles to the lungs 
1.4.2.1. Delivery of nanoparticle suspensions via nebulisation 
One method for the delivery of nanoparticles is nebulization of a nanoparticle 
suspension using a nebulizer.  Yamamoto et al. (2005) prepared surface modified 
PLGA NSs with chitosan to improve the pulmonary delivery of calcitonin by 
mucoadhesion after deposition in the lungs.  They administered nanoparticles into 
the trachea of guinea pigs using a nebulizer and showed that chitosan modified 
PLGA NSs-loaded with elcatonin, reduced blood calcium levels by 80% of the initial 
calcium concentration.  The treatment also prolonged the pharmacological action for 
up to 24 h, which when compared to unmodified NSs was significantly longer. They 
attributed these results to the retention of NSs by adhesion to the bronchial mucus 
and lung tissue combined with a sustained drug release at the adherence site.  In 
another study, McConville et al. (2006) formulated itraconazole nanoparticles using 
either evaporative precipitation into an aqueous solution (EPAS) or spray freezing 
into liquid (SFL) technologies. They demonstrated that nanoparticles of itraconazole, 
a poorly water-soluble drug, can be dispersed into aqueous liquid and nebulized 
effectively to the lungs using a murine model which resulted in high drug 





nanoparticles is a promising alternative to oral or intravenous administration, thus 
potentially decreasing the incidence of side effects associated with a high drug 
serum concentration (McConville et al., 2006). 
With regard to TB, Pandey et al. (2003) studied different routes for administration of 
treatment.  They compared different routes of administration with aerosol delivery of 
anti-tubercular drugs (rifampin, isoniazide and pyrazinamide) using loaded to PLG 
nanoparticles in guinea pigs.  The animals were treated with either a free drug orally 
or intravenously administered, nebulized drug-loaded PLG nanoparticles and 
nebulized empty PLG nanoparticles at the same dose. They sprayed the 
nanoparticle suspensions using a saline solution and a compressor powered-
nebulizing system with an exposure time of 3-4 min/ animal. The results showed that 
plasma Tmax and AUC were much higher for the nebulized PLG nanoparticles 
compared to oral or intravenous administration. In their study, they showed that five 
doses every ten days of nebulized drug-loaded nanoparticles had the same effect as 
46 daily oral doses. No colony-forming unit (cfu) count was detected in previously 
infected guinea pigs.  They repeated the study but instead of PLG nanoparticles they 
used solid lipid nanoparticles incorporating three major anti-TB drugs, rifampicin, 
isoniazid and pyrazinamide.  They showed that after a single nebulization to guinea 
pigs, drugs levels were maintained in plasma for 5 days and in the organs (lungs, 
liver and spleen) for 7 days, whereas the free drugs were cleared by 1–2 days. Also 
their study showed that mean residence time and bioavailability improved using 
nebulized nanoparticles. They showed that tubercle bacilli could not be detected in 
the lungs/spleen of infected guinea pigs after 7 doses of treatment every 7 days 





same therapeutic benefit. Therefore nebulization of nanoparticles containing anti-
tubercular drugs improves the bioavailability and reduces the dosing frequency for 
better management of pulmonary TB. Taking the results of the oral nanoparticle 
administration into account (discussed in Section 1.2.3) both results confirm that an 
improved drug delivery of the anti-TB drugs can be linked to the use of a 
nanoparticle based delivery system.  
However in spite of their initial promising results, the potential of these systems is 
limited by the nanoparticle instability in aqueous medium. Indeed, during storage 
aqueous suspensions of these colloidal particles present some disadvantages such 
as polymer hydrolysis leading to drug leakage and physicochemical instability due to 
the particle agglomeration and sedimentation. Therefore, the application of an 
effective technique or principle capable of prolonging the shelf life of these particles 
is of a considerable benefit (Pandey et al., 2003). 
 
1.4.2.2. Delivery of nanoparticles using dry powder carriers 
Pulmonary delivery of nanoparticles via different dry powder formulations has gained 
more attention in recent years.  Since nanoparticles are in a size range which is not 
suitable for deep lung delivery, the major challenge for pulmonary delivery of 
nanoparticles is to find a proper carrier system. Several researchers have prepared 
carrier systems for nanoparticles to improve the delivery of nanoparticles to the 
alveolar area. Kawashima et al. used ultrafine hydrophilic particles, 
hydroxypropylmethyl cellulose phthalate (HPMCP) nanospheres, to improve the 
aerosolization properties of a dry powder inhalation of a hydrophobic drug, 





nanospheres and then mixed the surface modified drug powder dispersion with 
lactose and then spray- or freeze-dried the suspension to obtain a dry powder. This 
powder was mixed with larger lactose particles for better dispersion when used in an 
inhaler. They performed an in vitro inhalation test using a twin impinger and showed 
that the inhalation properties of the surface modified powder dramatically improved. 
They showed that the emission of the powder increased two fold and that the dry 
powder delivery to the deep lung might increase 3 fold compared to the original 
unmodified powder. They attributed this improvement to the increased surface 
roughness and hydrophilicity of the surface-modified particles, which resulted in an 
increased dispersibility in air.  Tsapis et al. (2002) developed large porous carriers of 
nanoparticles for pulmonary drug delivery. They used a spray drying technique to 
produce large porous particles (LPP) which have extremely thin walled structures. 
They added two different surfactants, 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) and 1,2-dimyristoyl-sn-glycero-3-phophoethanolamine (DMPE), and lactose 
to the nanoparticles suspension and spray dried the mixture. The particles were 
made from nanoparticles which attached to each other via lactose and the 
surfactants when spray dried. They showed that the spray dried powder has suitable 
characteristics for pulmonary delivery and can be re-dissolved in a mixture of 
ethanol/water (Tsapis et al., 2002) 
The concept of administering nanoparticles incorporated into a carrier matrix for lung 
delivery was first introduced by Shama et al. (2005) for the preparation of the carrier 
powder containing nanoparticles (gelatin or iso-butyl cyanoacrylate), they dissolved 
lactose as a carrier powder in a nanoparticle suspension and spray dried it. They 





change significantly due to the heat involved in the spray drying process. This study 
proved the possibility of delivering and releasing nanoparticles in the lungs for 
applications such as treatment of lung cancer, cystic fibrosis or asthma (Azarmi et 
al., 2008). 
Grenha et al. (2005) incorporated insulin loaded chitosan nanoparticles in 
microspheres using aerosol excipients like lactose and mannitol by means of a spray 
drying technique for pulmonary delivery as a dry powder. They showed that the 
microencapsulation process does not affect the insulin release from nanoparticles. 
They propose this method for systemic delivery of macromolecules through the 
pulmonary route of administration to promote peptide absorption (Grenha et al., 
2005). 
1.4.3. In vitro measurement of particles aerodynamic diameter for 
aerosol systems 
Inertial impaction is the standard method to measure the particle or droplet 
aerodynamic size from pharmaceutical aerosol delivery systems (Barry et al.,1999).  
It describes the phenomenon of the deposition of aerosol particles on the walls of an 
airway conduct. The impaction tends to occur where the airway direction changes. 
The big particles have high momentum (inertia) and are more likely to travel in the 
initial direction of airflow, while those with low momentum adjust to the new direction 
of flow and pass around the obstruction. Inertial impaction employs Stokes’ law to 
determine the aerodynamic diameter of particles being evaluated. This has the 







1.5. Aim and scope of the thesis 
The failure of anti-tubercular chemotherapy is mainly due to poor patient compliance, 
which is attributed to the requirement for multidrug administration daily for at least six 
months.  The high frequency of pulmonary TB demands the development of novel 
drug delivery approaches that enhance the bioavailability of drugs in the lungs.  In 
recent years, one of the best ways to achieve higher sustained drug levels in the 
lungs has been the development of particulate-based formulations that are directly 
delivered to the lungs via the inhaled route.  Nanoparticles represent a class of drug 
delivery vehicles which can serve as promising vehicles for ferrying large doses of 
the drug to the target site with interception of minimal side effects. As a drug delivery 
carrier they offer several advantages, such as ease of purification and sterilization, 
possibility of drug targeting, and a sustained release action.  However, a possible 
obstacle to using nanocarriers for pulmonary delivery is that their MMAD is too small 
for extensive particle deposition in the lungs. 
The overall aim of this thesis was to develop novel PVA nanoparticles for the 
pulmonary delivery of rifampicin for the treatment of Mycobacterium Tuberculosis.  
The limitations of delivering nanoparticles to the lungs will be solved by incorporating 
the developed rifampicin-loaded PVA nanoparticles in an inert carrier to produce 
particles in the micrometer size of a suitable size for deposition in the alveolar 
regions of the lungs.  The formulation was designed such that after deposition in the 
lung, the carrier matrix will dissolve readily releasing the nanoparticles, which will 
deliver the therapeutic payload in a controlled manner.  It was hypothesized that 






The specific objectives of this thesis were as follows: 
1. To develop and characterise novel rifampicin-loaded PVA nanocarriers.  
2. To evaluate the biocompability and interaction of the nanocarriers with  
macrophage-like cells. 
3. To encapsulate the nanocarriers into microspheres and characterise the dry 








































2.1.  Introduction 
 
Rifampicin, the key component in the combination treatment of TB and leprosy 
recommended by the World Health Organization (WHO, 2003; Venkatesan, 1989), 
was used in this thesis as a clinically relevant model drug to investigate 
nanomedicines.  High Performance Liquid Chromatography (HPLC) was employed 
throughout the thesis for the analysis of this drug and monitoring of its degradation.  
In this Chapter, the method development for this technique is outlined.  It was 
anticipated that the HPLC method would be applied in a number of important 
subsequent experiments to address the main aims of the thesis.  Drug stability in 
different matrices and drug solubility at different pHs were also investigated to 
underpin key analytical procedures such as drug loading and release studies which 
are crucial when delivering medicines using colloids. 
 
Rifampicin (Figure 2.1) is a complex semi-synthetic macrocyclic antibiotic derived 
from streptomyes mediterranei.  It is a member of the rifamycin class of antibiotics 
used for treatment of TB, staphylococcal endocarditis, osteomyelitis and 
chemoprophylaxis of meningitis caused by Haemophilus influenza (Mandell et al., 
1985).   Depending on its indication, the dose varies from 10 mg/kg daily to 15 to 30 
mg/kg divided into three doses for other uses (British National Formulary, 2011). 
 
Rifampicin is amphoteric with a pKa1 of 1.7 (4-hydroxyl group) and a pKa2 of 7.9 (3-
piperazine nitrogen) (Oppolzer and Prelog., 1973; Pelizza et al., 1977).  It is a 





is classified as a class II drug in the Biopharmaceutical Classification System (BCS) 
(Kasim et al., 2004).  Rifampicin chemical stability and its pH dependent solubility 
are two major factors contributing to its low bioavailability and poor therapeutic 





Figure 2.1.  Chemical structure and summary of the physico-chemical 
characteristics of rifampicin 
 
Rifampicin exists in aqueous solutions as a zwiterrion with an iso-electric point of 4.8 
(Maggi et al., 1966; Fourie et al., 1999; Howes et al., 2007).  At basic pH values a 
zwitterionic agent behaves primarily as an acid whereas at low pH values it behaves 
as a base.  A number of studies have reported the solubility of RFP at 370C in 
buffered media of different pHs (Table 2.1) (Mariappan and Singh, 2003; Agrawal 
and Panchagnula, 2005).  However, these studies did not appear to consider the 
influence of chemical degradation.  Rifampicin is known to form a number of 
degradants in the solution state (Bain et al., 1998; Gharbo et al., 1989; Seydel, 1970; 
Nahata et al., 1994).   Two major decomposition products exist: 3-formylrifamycin SV 
 
 Molecular formula: 
C43H58N4O12 
 MW: 822.96 




 Log P: 3.179 







(RSV) and rifampicin quinone (RQU) formed by hydrolysis and oxidation respectively 
(Seydel, 1970).  RSV, which results from the hydrolysis of the 4-
methylaminopiperazine moiety in acidic medium, is insoluble and has poor 
absorption (Maggi et al., 1966).  It shows high antimicrobial activity in vitro (Maggi et 
al., 1965) but it is inactive in vivo (USP DI, 1996).  RQU, which is formed in alkaline 
medium in the presence of oxygen, is purple and inactive, due to the fact that the 
free hydroxyl groups on C1 and C8 are essential for binding the drug to bacteria 
(Foye et al., 1995). A third decomposition product 25-desacetylrifampicin (DAR) is 
formed in alkaline medium in the absence of oxygen.  The two agents 25-desacetyl-
21-acetylrifampicin (25-21) and 25-desacetyl-23-acetylrifampicin (25-23), formed 
sequentially from DAR, both have negligible antimicrobial activity (Gallo and 
Radaelli, 1968).  HPLC has been used to analyse the stability of RFP (Bain et al., 


























HCl, NaCl, H2O 
HCl, citric acid, NaOH, NaCl, H2O 
HCl, citric acid, NaOH, NaCl, H2O 
HCl, citric acid, NaOH, NaCl, H2O 
NaCl, Na2HPO4,H2O 
NaCl, Na2HPO4 ,H2O 
127.21 
  42.68 
  19.21 
    3.19 
    0.64 



















Sodium citrate/citric acid buffer 
Sodium citrate/citric acid buffer 
Sodium citrate/citric acid buffer 







  11.40 
  11.40 
    1.15 
    0.75 
    0.99 
    1.25 
    1.53 
    1.65 
    2.54 
    3.35 
    5.44 
 







The aim of the Chapter was to establish HPLC techniques for rifampicin 
quantification, solubility testing and chemical degradation assessment.  It was 
anticipitated that these methods would be applied to address the main aims of the 
thesis.    The specific objectives of this Chapter were: 
 To develop and prove ‘fit for purpose’ an HPLC method for the quantification of 
rifampicin. 
 Determine the solubility of rifampicin in aqueous solutions of different pHs. 
 Establish the effect of a number of experimental conditions on rifampicin 
recovery. 
 To develop and prove ‘fit for purpose’ an HPLC method for the co-analysis of 





2.2. Materials  
 
Rifampicin (95% pure) was purchased from Sigma-Aldrich (UK) and 3-
formylrifamycin SV was from the British Pharmacopoeia Commission Laboratory 
(UK).  L-Ascorbic acid, sodium citrate dehydrate, citric acid and butylhydroxytoluene 
were obtained from Sigma-Aldrich (UK).  Phosphate Buffered Saline tablets were 
from Oxoid Ltd (UK).  Acetonitrile (HPLC grade) and methanol were purchased from 











2.3.1. HPLC analysis of rifampicin 
HPLC quantification of rifampicin was performed using a 600 HPLC pump (Waters, 
UK) with a 717 auto-sampler (Waters, UK) and a 2487 dual  absorbance detector 
(Waters, UK).  The column used was a reversed-phase C18 (250 x 4.6 mm).  UV-
photodiode array detection was performed at 254 nm.  The mobile phase consisted 
of acetonitrile: citrate buffer (35:65 % v/v) at a flow rate of 1 ml/min.  Final pH of the 
mobile phase was adjusted to 6.2 by diluted hydrochloric acid.  Column temperature 
was set to 28°C and a 10 μl sample injection volume was employed throughout. 
 
Calibration standards were produced using a 1 mg/ml rifampicin stock solution in 
acetonitrile (containing 0.02% w/v butylhydroxytoluene (BHT) to avoid drug 
oxidation).  Six serial dilution of the rifampicin stock generated calibration standards 
in the range of 1-0.01 mg/ml.  Calibration plots were constructed for rifampicin in 
standard solutions by plotting the concentration of compound versus peak area 
response.  The linearity of the calibration plots were evaluated using least square 
regression analysis.  Three calibration curves were run on a single day to determine 
the intra-day sample variance; this data was combined with two additional calibration 
curves on two further days to determine the inter-day sample variance.   
 

























Accuracy     (2.2) 
where sd is the standard of deviation; Mean is the mean peak area; T is the 
theoretical concentration of analyte and A is the actual concentration of analyte.  
Limits of detection (LOD) and quantification (LOQ) were calculated according to 
equations 2.3 and 2.4: 
 
BB sYLOD 3      (2.3) 
 
BB sYLOQ 10      (2.4) 
 
where SB is the standard error of the y estimate and YB is the intercept from the 





.       (2.5) 
 
where W0.05 is the width of the peak at one-twentieth of the peak height and d the 
distance between the perpendicular dropped from the peak maximum and the 
leading edge of the peak at one-twentieth of the peak height.  Theoretical plate 












N      (2.6) 






2.3.2. Determination of rifampicin aqueous solubility 
A series of rifampicin saturated aqueous solutions at different pHs (pH 2.5-7.4, citric 
acid-phosphate buffer, 0.5 M) were prepared by adding an excess of drug to a 15 ml 
scintillation glass vials containing 10 ml buffer. The suspensions were agitated for 24 
hours and hydrochloric acid was used to adjust any pH drift when appropriate. The 
samples were filtered using 0.2 μm cellulose acetate syringe filter (Fisher scientific, 
Leicestershire, UK), diluted using mobile phase and analysed by HPLC. All samples 
were stored under light protected conditions at ambient temperature (23 ± 2oC) 
during the solubility study (n = 3).   
 
The percentage of rifampicin ionisation values for rifampicin’s two functional groups 
(4-hydroxy group and 3-piperazine nitrogen group) at each test pH were calculated 
using Eq. (2.7 and 2.8).  A pKa of 1.7 was used for the 4-hydroxy group and 7.9 for 
the 3-piperazine nitrogen group:  
 
                                      
        
          
                     (2.7) 
 
                              
        
          
    (2.8)   
  
where Ionisation% was the percentage of a functional group ionisation in an aqueous 







2.3.3. Chemical stability of rifampicin 
The chemical stability of rifampicin was determined in the absence and presence of 
an anti-oxidant in aqueous solutions.  Either 0.02 or 0.2 % w/v of ascorbic acid were 
added to a 1 mg/ml solution of rifampicin in PBS buffer (pH 7.4).  The solutions were 
constantly stirred and at pre-determined time point (0, 6, 24, 48 and 72 h), samples 
were withdrawn from the solutions, diluted using mobile phase and analysed by 
HPLC.  All samples were stored under light protected conditions at ambient 
temperature (23 ± 2oC) during the stability study (n = 3).  The effect of rifampicin 
concentration and temperature on drug stability was also investigated by using two 
drug concentrations of rifampicin (1 mg/ml and 0.01 mg/ml) containing 0.02 % w/v 
ascorbic acid at two different temperatures, ambient temperature (23 ± 2oC) and 
37oC.   
 
The hydrolysis of rifampicin was also investigated in PBS buffer (pH 7.4).  For the 
co-analysis of rifampicin and RSV, a second HPLC method was developed.  
Analysis was performed using a 600 HPLC pump (Waters, UK) with a 717 auto-
sampler (Waters, UK) and a 2487 dual  absorbance detector (Waters, UK).  The 
column used was a reversed-phase C18 (250 x 4.6 mm).  UV-photodiode array 
detection was performed at 240 nm.  The mobile phase consisted of acetonitrile: 
PBS buffer (36:64 % v/v) at a flow rate of 1.4 ml/min.  Final pH of the mobile phase 
was adjusted to 7.5 by diluted hydrochloric acid.  Column temperature was set to 
28°C and 10 μl of samples was injected to the HPLC system.  Calibration standards 
were produced by making up a stock solution in acetonitrile containing 1 mg/ml 





oxidation). Six serial dilutions were used to produce calibration standards in the 
range of 1-0.01 mg/ml.  Calibration plots were constructed for rifampicin and RSV in 
standard solutions by plotting the concentrations of the compounds versus peak area 
response.  The linearity was evaluated by linear regression analysis, which was 
calculated by the least square regression method.  Three calibration curves were run 
on a single day to determine the intra-day variance; this data was combined with two 
additional calibration curves on two further days to determine the inter-day variance.  
Precision and accuracy were calculated according to equations 2.1 and 2.2.  Limits 
of detection (LOD) and quantification (LOQ) were calculated according to equations 
2.3 and 2.4.  
 
2.3.4. Data analysis and statistics 
 
All data was expressed as mean ± standard deviation (S.D.)  Statistical analysis was 
performed in SPSS, version 16.0, using either student t-test or an analysis of 










2.4.1. HPLC analysis of rifampicin 
A single peak was eluted in the HPLC chromatogram (Figure 2.2) with a retention 
time of 6.66 ± 0.3 min (n=210).  The peak shape had a high degree of symmetry (As 
ranged from 0.88 to 1 (n=10)) and column efficiency remained constant throughout 
the study, N=650 ± 27 (n=10, two from each of the five calibration runs).  The 
calibration curve displayed excellent linearity over the concentration range of 1-0.01 
mg/ml, with correlation coefficient of >0.999 for the peak area calculations (Figure 
2.3). 
 
The calculated LOD value was 5.4 µg/ml while the LOQ was 18 µg/ml using peak 
area.  The results obtained for assay precision and accuracy are presented in Table 
2.1.  The data illustrates that precision of the peak area measurements was very 
similar at all concentrations.  The method has an average of 1.4 ± 0.9% for intra-day 
precision, 1.9 ± 0.8% for inter-day precision and a 99.5 ± 1.9 % mean accuracy 







Figure 2.2. Typical high performance liquid chromatography chromatogram of a 
rifampicin standard (rifampicin 1 mg/ml in acetonitrile with 0.02% w/v butylhydroxy 





Figure 2.3.  Calibration curve for the HPLC assay for rifampicin.  Data represent 
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  99.1 
102.0 
101.5 
  97.8 
  96.8 
 
Table 2.2.  Inter- and intra-day variation in the HPL assay for rifampicin based on 
peak area (intra-day: 3 x calibration curves on day 1, inter-day: 3 x calibration curves 
on days 1, 2 and 3 respectively, n=6 at each concentration). 
 
 
2.4.2. Aqueous solubility of rifampicin  
In the pH range of 2.5- 4.5, the aqueous solubility of rifampicin decreased as the pH 
of the aqueous vehicle in which it was dissolved increased (Table 2.3).  In contrast, 
in the pH range of 4.5-7.4, the drug aqueous solubility increased as the pH increased 
(Figure 2.4).  The lowest rifampicin aqueous solubility (0.75 mg/ml) was obtained at 


































































































Figure 2.4. The aqueous solubity of Rifampicin at different pHs (n=3) 
 
2.4.3. Chemical stability of rifampicin 
In the absence of the anti-oxidant, rifampicin (1 mg/ml) recovery at PBS buffer pH 
7.4 decreased by approximately 24% over 72 hr (Table 2.4).  The addition of 
ascorbic acid (0.02% w/v) significantly increased rifampicin recovery (p < 0.05) 
Further increase of the anti-oxidant concentration to 0.2 % w/v had no significant 
effect on the drug recovery.   
 
Rifampicin degradation at pH 7.4 was concentration dependant (table 2.5).  At higher 
concentration (1 mg/ml) in the presence of an anti-oxidant (0.02 % w/v), rifampicin 


































degradation rate was significantly higher, 66 ± 2.1 %.  The temperature also seems 






Rifampicin recovery (%) 









99.2 ± 0.82 
92.3 ± 1.36 
86.0 ± 1.12 
82.6 ± 1.89 
76.3 ± 1.20 
 
99.9 ± 0.95 
96.7 ± 1.05 
94.3 ± 1.42 
91.6 ± 1.92 
88.3 ± 2.14 
 
99.8 ± 0.64 
97.7 ± 1.35 
93.3 ± 1.55 
92.6 ± 1.83 
89.3 ± 1.94 
 
 
Table 2.4.  Percentage recoveries of rifampicin (1 mg/ml) at ambient temperatures 
























99.9 ± 0.95 
96.7 ± 1.05 
94.3 ± 1.42 
91.6 ± 1.92 
88.3 ± 2.14 
 
96.9 ± 2.4 
93.5 ± 0.1 
86.5 ± 1.9 
72.5 ± 0.5 
66.0 ± 2.1 
 
      101.9 ± 4.4 
99.6 ± 4.6 
96.7 ± 4.2 
92.9 ± 4.4 
89.7 ± 4.6 
 
 
97.3 ± 1.8 
92.6 ± 1.8 
68.7 ± 1.2 
59.1 ± 4.5 
54.6 ± 8.0 
 
 









For the co-analysis of rifampicin and RSV two peaks were eluted in the HPLC 
chromatogram with retention times of 5.81 ± 0.4 min (n=210) for rifampicin and 9.66 
± 1.5 min (n=210) for RSV.  The peaks shapes had a good degree of symmetry (As 
ranged from 0.81 to 1 (n=20)) and column efficiency remained constant throughout 
the study, N=545 ± 36 (n=20, Four from each of the five calibration runs).  The 
calibration curves were linear over the concentration range of 1-0.03 mg/ml, with 
correlation coefficients of >0.999 for the peak area calculations for both rifampicin 
and RSV (Figure 2.5).  The calculated LOD values were 2.8 µg/ml and 1.2 µg/ml, for 
rifampicin and RSV, respectively.  The LOQ values were 10.2 µg/ml and 8.4 µg/ml, 
for rifampicin and RSV, respectively.  The precision and accuracy were very similar 






















Figure 2.5.  Summation of the area of five calibration curves (n=6 for each 
concentration of each calibration curve) for the peak area calculations for rifampicin 
and RSV (data represent mean ± sd, n=5) 
  





















































Intra-day precision and 
accuracy 
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  97.4 
  96.4 
 
Table 2.6.  Inter- and intra-day variation in the rifampicin assay based on peak area 
(intra-day: 3 x calibration curves on day 1, inter-day: 3 x calibration curves on days 1, 










Intra-day precision and accuracy 
 










































































Table 2.7.  Inter- and intra-day variation in the RSV assay based on peak area (intra-
day: 3 x calibration curves on day 1, inter-day: 3 x calibration curves on days 1, 2 









Rifampicin hydrolysis was investigated in PBS buffer (pH 7.4) over 72 h at room 
temperature.  As it can be seen from figure 2.6 rifampicin concentration was 
decreased from 0.78 mg/ml to 0.65 mg/ml over a 72 h period.  In contrast, RSV 




Figure 2.6.  The hydrolysis of rifampicin (0.8 mg/ml) in phosphate buffer (pH 7.4) 


































The aim of the Chapter was to establish HPLC techniques for rifampicin analysis, 
solubility testing and chemical degradation assessment. In the first HPLC assay, the 
hydrophobic C18 column and the polar mobile phase employed were found to be 
appropriate for the separation of rifampicin.  There was a good linearity for the 
concentration range studied, acceptable limit of detection and quantification.  The 
mean accuracy, the intra and inter-day variation all complied with the acceptance 
criteria proposed in harmonised analytical guidelines (R.S.D.: not more 2.0%, 
recovery: 100 ± 2 %) (Drugs Directorate, 1994).  The rapidity, the simplicity and 
efficacy of the developed method as well as the short retention time of RFP permit 
the analysis of a large number of samples in a short time period providing a fast and 
inexpensive method for RFP quantification in this project. 
The rifampicin solubility at 370C in buffered media of different pHs correlated well 
with the ionisation profiles of the two functional groups 4-hydroxyl group and 
piperazine groups.  At pH 1 to 4 rifampicin behaves as a base as the number of 
ionised piperazine groups is higher than the number of ionised 4-hydroxyl groups.  At 
pH range of 4 to 6 both functional groups are ionised which makes the molecule 
neutral with a low aqueous solubility.  Rifampicin exhibited minimal solubility (0.7 
mg/ml) at pH 4.5.  At pH 6 to 12 rifampicin behaves as an acid.  The trend of our 
solubility data also correlated well with the previous data reported (Mariappan and 
Singh, 2003; Agrawal and Panchagnula, 2005).  The differences in values reported 
could be due to of the different polymorphic forms used.  Additionally, the pH was 
maintained constant throughout this study, while this was not documented in other 





solvent interactions.  In previous work this has been used to facilitate drug loading 
into nanocarriers (Govender et al., 1999; Zhao et al., 2010).    
The extent of chemical degradation was investigated in a number of different 
aqueous matrices over a period of 72 h.  These matrices varied in the concentration 
of the anti-oxidant, drug concentration and temperature.  Rifampicin degradation was 
shown to be accelerated at lower concentrations.  The change in temperature also 
seems to have a significant effect on the rate of rifampicin degradation.  The addition 
of ascorbic acid (0.02% w/v) significantly increased rifampicin recovery by in 
comparison with the control (without antioxidant) during the 72 h study.  This data 
suggests that ascorbic acid, at a concentration of 0.02% w/v, should be used in 
aqueous solutions in order to retard drug oxidation.  Bain et al. (1989) showed that 
ascorbic acid had the greatest activity (t1/2 = 69.3h) in preventing oxidation of 
rifampicin to RQU in comparison with sodium metabisulphate ((t1/2 = 4.85h) and the 
control (t1/2 = 2.45h).  This previous work showed that 0.1% w/v was adequate for 
anti-oxidant protection (Bain et al., 1998).  High antioxidant was required in the 
previous study as the experiments were run for few weeks (Bain et al., 1998).    
Despite the presence of the anti-oxidant, only 88.3 ± 2.14 % was recovered after 72 
h storage at ambient temperature, which suggests the presence of second 
degradation pathway other than oxidation.       
For the co-analysis of rifampicin and its hydrolysis degradant RSV, a second HPLC 
method was developed.  The use of a C18 stationary phase packing and the simple 
mobile phase of pH7.5 resulted in adequate resolution of both RFP and RSV whilst 





concentration range studied, with correlation coefficients greater than 0.999.  The 
calculated LOD and LOQ values for rifampicin and RSV were acceptable.  The mean 
accuracies, the intra and inter-day variation all comply with the acceptance criteria 
proposed (R.S.D.: not more 2.0%, recovery: 100 ± 2 %)(Drugs Directorate, 1994).   
Rifampicin hydrolysis is claimed to occur in acidic condition (Gharbo et al., 1989; 
Seydel, 1970; Krubenberg et al., 1996; Nahata et al., 1994; Prankerd et al., 1992).  
However, it was shown that the reduced recovery of rifampicin was associated with 
the formation of RSV at pH 7.4 (37oC) over 72 h period.  This provides some 
evidence that hydrolysis was occurring at pH 7.4 and hence the HPLC method 
developed for the co-analysis of rifampicin and RSV will be employed in subsequent 
chapters for the quantification of rifampicin and its degradant.  Since rifampicin 
degrades rapidly rapidly in aqueous solution, fresh calibration standards were 
prepared on the day of every experiment and constructed calibration curves will be 












This chapter established the methodology for techniques that will be used for the 
quantification of rifampicin and monitoring its degradation. The developed HPLC 
methods will be will be applied to address the problems of loading and release of 
drug from nanomedicines.  The rifampicin recovery from several aqueous matrices 
was also established.  Solubility-pH relation was determined and the data obtained 
will be used at different stages of this project to maximize rifampicin loading in the 
particles and to control its release.  
Rifampicin degradation in aqueous solution could be responsible for the sub-
therapeutic concentrations reaching the lung and the variable bioavailability.  
Therefore the encapsulation into a carrier would provide a protective coat for the 
drug to reduce its degradation after administration.  To achieve that, rifampicin will 
be encapsulated into new PVA nanocarriers.  The loading and release of the drug 






















Rifampicin is the first-line agent in the treatment of TB, but it requires a high oral 
dose (600 mg daily) over a long period (4–6 months).  Owing to the high incidence of 
side effects (immunological disturbances, allergic rashes, rheumatoid, or lupoid 
syndromes, eosinophilia, leukopenia, and other hepatotoxic manifestations) and the 
need for long-term daily dosing, patient non-compliance, relapse of symptoms and 
an alarming increase in the prevalence of multidrug-resistant strains are problems 
associated with TB therapy (Barrow et al., 1998; Laura et al., 2000).  With the aim of 
maximizing the therapeutic indices and minimizing the associated side-effects, a 
number of rifampicin-containing delivery systems (liposomes, dendrimers and 
particulate systems) have been developed and characterized (Barrow et al., 1998; 
Denkbas et al., 1995; Deol and Khuller, 1997; Suarez et al., 2001; Sreenivasa et al., 
2002; Vyas et al., 2004).  The focus of previous research is the fabrication of a 
delivery vector for rifampicin, but several systems have been shown to have a the 
short half life, stability issues, leakage of encapsulated drugs and high production 
costs (Vyas et al., 2004). 
 
Nanoparticles can act as rigid delivery vectors with the potential to enhance drug 
bioavailability, increase the residence of rifampicin in the lung, may help address 
issues associated with the problem of non-adherence to prescribed therapy and thus 
improve patient compliance (Ahmad et al., 2008; Gelperina et al., 2005; Pandey and 
Khuller, 2007; Soppimath et al., 2001).  Several previous studies have documented 
the use of drug-loaded nanoparticles to modify the pharmacokinetics of anti-





investigated the pharmacokinetics and antibacterial effect of nanoparticle-bound anti-
TB drugs administered via the respiratory route in guinea pigs (Pandey et al., 2003).  
A single dose of rifampicin, isoniazid and pyrazinamide co-encapsulated in poly(DL-
lactide-co-glycolide) (PLGA) nanoparticles administered via nebulization to guinea 
pigs resulted in sustained therapeutic drug levels in the plasma for 6-8 days and in 
the lungs for up to 11 days.  The elimination half-life and mean residence time of the 
drugs were significantly prolonged compared to oral administration, resulting in 
enhanced relative bioavailability (12.7-, 32.8- and 14.7-fold for rifampicin, isoniazid 
and pyrazinamide, respectively).  On nebulization of the drug-loaded nanoparticles to 
M. tuberculosis infected guinea pigs at 10 day intervals, no tubercle bacilli could be 
detected in the lung after five doses of treatment whereas, 46 daily doses of orally 
administered drug were required to obtain an equivalent therapeutic benefit.  Zahoor 
and co-workers (2005) also showed that the relative bioavailability of anti-tubercular 
drugs encapsulated in alginate nanoparticles were significantly higher compared with 
oral administration of free drugs.  A 16.5-fold increase in the relative bioavailability of 
rifampicin, administered by inhalation, was achieved (Zahoor et al., 2005).  Sharma 
and colleagues (2004) demonstrated that the administration of three doses of 
nebulized rifampicin, isoniazid and pyrrazinamide co-encapsulated in wheat germ 
agglutinin-functionalised PLG nanoparticles, fortnightly for 45 days, could be 
sufficient to produce a sterilising effect in lungs and spleen (Sharma et al., 2003).  A 
sterilising effect was also achieved when the drugs were loaded in solid lipid 
nanoparticles.  No tubercle bacilli could be detected in the lungs/spleen after seven 
doses of treatment of infected guinea pigs with drug-loaded solid lipid nanopraticles 





features of human TB.  In addition, the nanoparticulate systems used in these 
studies were not fully characterised in terms of drug content, nanoparticle yield, 
stability and drug recovery.  The problem of retaining the active form of rifampicin in 
the particles during formulation storage and the release of the drug upon 
administration was not addressed in the previous study. 
 
PLGA has previously been used to manufacture nanocarriers in which the anti-
tubercular drugs were encapsulated (Esmaeili et al., 2007; Pandey et al., 2003; 
Sharma et al., 2003; Tomoda et al., 2008).  However, the long residence of PLGA in 
the lung due to its slow degradation (Dunne et al., 1996), can lead to pulmonary 
accumulation of the polymer, especially with chronic daily administration.  Other 
biocompatible polymers for the encapsulation of anti-TB drugs are therefore 
necessary.  
  
Poly (vinyl alcohol) (Figure 1), is a synthetic semi-crystalline co-polymer prepared by 
the polymerisation of vinyl acetate and the subsequent hydrolysis of poly (vinyl 
acetate).  PVA with different physicochemical properties can be produced by varying 
the length of the initial vinyl acetate polymer, the degree of hydrolysis and the 
method used to obtain the hydrolysis i.e under alkaline or acidic conditions (Wong et 
al., 1996).  The polymer’s biocompatibility has made it an excellent material for use 
in a wide range of industrial, commercial, medical and food applications.  PVA is 
currently used globally for coating pharmaceutical products and dietary supplement 
products regulated as pharmaceuticals.  It is also approved by the Food and Drug 





Thanoo et al., 1993; Ficek and Peppas, 1993).   Published studies on the absorption, 
distribution, excretion, acute, subchronic and mutagenicity of this co-polymer indicate 
that it is relatively non-toxic by the oral route (DeMerlis and Schoneker, 2003).   
 
    
Figure 3.1. Chemical structure of poly (vinyl alcohol) 
 
The aim of the experimental work presented in this chapter was to develop and 
characterize new rifampicin-loaded PVA nanocarriers.  PVA had not previously been 
used to deliver a therapeutic agent and was selected for the preparation of the 
nanocarriers because of its biocompability and its potential to modify drug release.  A 
hydrophobic grade of PVA (40 % hydrolysed) was used in this work for the 
manufacture of nanospheres (NS) and nanocapsules (NC) using solvent 
displacement technique (Fessi et al., 1989).   The specific objectives of the 
experimental work in this chapter were to: 






• Perform nanoparticle characterization by determining the particle size and 
polydispersity, zeta potential, physical stability (4oC and 25oC) and morphological 
evaluation of the particles. 
• Load the nanoparticles with rifampicin and determine drug encapsulation 
efficiency, drug content. 







3.2. Materials  
 
Rifampicin (95% pure) was purchased from Sigma-Aldrich (UK) and PVA 40% 
hydrolyzed (PVA-40) (MW 72,000) was from polysciences (UK).  PVA 80% 
hydrolyzed (PVA-80) (MW 9,000-10,000) was supplied by Aldrich (USA) and Fluka 
(Switzerland), respectively.  Acetonitrile (HPLC grade) and methanol were 
purchased from Rathburn Chemicals Ltd (UK) and VWR International Ltd (UK).  
Sodium citrate dehydrate, citric acid and butylhydroxytoluene were obtained from 
Sigma-Aldrich (UK).  Phospholipids (Epikuron 200) were supplied by Degussa 





















3.3.1. Preparation of PVA nanocarriers 
 
The rifampicin-loaded NSs were prepared according to a modified solvent 
displacement technique (Fessi et al., 1989).  This method required 50 mg PVA-40 to 
be dissolved in 5 ml of methanol using stirring for 12 h for complete dissolution of the 
polymer.  Different amounts of rifampicin (5, 10, 25 and 50 mg) were dissolved in this 
polymeric solution and injected into a dispersing phase (30 ml) containing citrate 
buffer (pH 4.8), 1 % w/v of PVA-80, at a speed of 0.5 ml/min using a 5 ml syringe 
housed in a syringe driver (Precidor, Infors, Basel, Switzerland).  PVA nanocapsules 
were prepared using a similar method, with few modifications (Fessi et al., 1989).  
PVA (50 mg), phospholipids (75 mg) and rifampicin (5, 10 and 25 mg previously 
dissolved in 0.33 ml of benzyl benzoate) was added to 15 ml of acetone to form the 
organic phase.  To form the nanocapsules the acetone mixture was injected into 
30 mL of an aqueous solution composed of poloxamer 188 (0.5 % w/v in citrate 
buffer, pH 4.8) under moderate homogenization (5,000 rpm).  Both mixtures used to 
form NSs and NCs were homogenized at 5000 rpm for 10 min using a Silverson 
L4RT laboratory mixer (Silverson Machines Ltd, Waterside, UK), stirred overnight in 
the fume hood for complete evaporation of the organic solvent and filtered through 1 
µm cellulose filter to remove any large aggregates.  Drug-free nanoparticles were 
prepared according to the same procedure omitting the drug. 
The drug-loaded nanoparticles were separated from the free drug by an 





ultra 15®) with MWCF (molecular weight cut-off) of 100 kDA (Fisher Scientific, UK) at 
3000×g for 1 h (MSC centaur 2 centrifuge, DJB Labcare Ltd., UK).  In this system, 
the non-encapsulated rifampicin is passed through the filter and the nanoparticles 
retained on the filter are re-suspended in 1 ml of water.   
 
In order to determine the mass of nanoparticles recovered from the process, several 
batches of concentrated nanosuspensions were freeze-dried for 24 h.  The 
nanoparticle recovery (nanoparticle yield) was calculated according to equation 3.1: 
 
 
                                            
  
   
                               (3.1) 
 
Where Wn is the mass of nanoparticles recovered and Wt  is the mass of particle 
forming excipients used in the fabrication process. 
 
A second sequence of concentrated nanosuspensions was diluted with ethanol and 
drug encapsulated was quantified using the validated HPLC assay.  A mass balance 
of the drug was calculated from the process to get the total drug recovery after 
encapsulation and purification.  
 
The drug content (DC), encapsulation efficiency (EE), Concentration (CC) and drug 
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Where V is the final volume of purified nanosuspension, W1 is the mass of the drug 
in the purified nanoparticles, W2 is the mass of the drug in aqueous filtrate, W3 is the 
mass of the drug in the wash, W0 is the mass of initial drug input and Wn is the mass 
of nanoparticles on the filtrate.  
 
3.3.2. Physicochemical characterisation of nanocarriers 
3.3.2.1. Photon Correlation Spectroscopy 
The average volume diameters and the polydispersity index of nanoparticles were 
determined by Photon Correlation Spectroscopy (PCS) (Zetasizer Nano, Malvern).  





particle or droplet in solution (Finsy, 1994).  By assuming spherical aggregates, the 
measured D can be used to calculate the hydrodynamic diameter, d(H), of the 
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Where d(H) is the hydrodynamic diameter, D is the translational diffusion coefficient, 
k is Boltzman’s constant, T is the absolute temperature and π is the viscosity.  To 
determine the absolute diameter, serial dilutions (1 in 8, 1 in 16, 1 in 32 and 1 in 64) 
of each sample were made with filtered water. The analysis was performed at a 
scattering angle of 90° and at a temperature of 25°C.  For each diluted sample, the 
mean hydrodynamic diameter ± standard deviation of ten determinations were 
calculated. The obtained diameters were plotted against the concentration and the 
intercept (zero concentration) was taken as the absolute diameter. 
 
 
3.3.2.2. Zeta potential 
Samples were analyzed following appropriate dilution with 1 mM NaCl and filtration 
through 0.2 µm filter, using a Zetasizer Nano, Malvern.  Values reported are the 









3.3.2.3. Morphological evaluation 
The morphology of the nanoparticles was examined by cryo electron microscopy 
(cryo-EM).  A drop of nanoparticle suspension (10 µl) was placed on a copper grid 
covered with carbon support film. Liquid nitrogen was used for freezing the specimen 
grid which was then maintained at a temperature of  −176 °C using a Gatan 626 
side-entry cryo holder (Gatan Inc., Pleasanton, USA).  Images were acquired using 
an FEI Tecnai G2 T20 electron microscope (FEI Company, USA) operating at 
200 kV. The microscope is equipped with a Gatan Ultrascan 2k × 2k CCD camera 
(Gatan Inc., Pleasanton, CA, USA).  Samples were viewed under low-dose 
conditions at a constant temperature around   −170 °C.  
 
3.3.2.4. Physical stability 
Four formulations were selected for this study: blank NS, blank NC, NS-3 and NC-3 
(Table 3.2).  Physical stability was assessed by comparing the initial particle size 
with those obtained after 1, 3 and 7 d storage at 25°C and 4°C.  The results were 
analysed for statistical significance using the statistical analysis (Student’s t-test) 
where the differences are considered insignificant when p > 0.05. 
 
3.3.3. In vitro rifampicin release   
To characterize rifampicin release from the particles, a 30 ml batch of freshly 
prepared nanosuspension loaded with 25 mg of rifampicin (NS-3 and NC-3, Table 
3.2) was concentrated to 1 ml using the Amicon Ultra YM-100 centrifugal 
concentrators.  At t=0, the concentrated nanosuspensions were spiked into a 5 ml 





suspensions were stirred in a water bath at 37oC and drug release was determined 
over a series of time points.  The pH values were selected to simulate physiological 
(pH 7.4) and endosomal pH of alveolar macrophages (pH 4.2).  At t=0, 2, 4, 6, 24 
and 48 h a 0.2 ml sample was withdrawn from the suspensions.  The nanoparticles 
were separated from the free drug using 0.5 ml centrifugal concentrators with MWCF 
of 100 kDA (Amicon Ultra 0.5 ml) at 3000×g for 5 min. The drug content in the 
nanoparticles and the dispersing medium and were analysed by HPLC.  Drug 
remaining in the nanoparticles was calculated at each time point (n = 3) according to 
equation 3.7 and plotted againt time (h) 
 
 
       
  
  
        (3.7) 
 
Where Wd is the percentage mass of the drug remaining in the nanoparticles, Mt  is 
the mass of drug in the nanoparticles at a time point and M0  is the mass of drug in 
the nanoparticles at t0. 
In order to trigger the release of rifampicin from the PVA nanocarriers using an 
exogeneous triggering system, the drug-loaded nanoparticles were resuspended in 
two different media: glycine-NaOH buffer (pH 10) and glycine-NaOH buffer: ethanol 









3.3.4. Rifampicin assay 
 
HPLC quantification of rifampicin was performed using a 600 HPLC pump (Waters, 
UK) with a 717 auto-sampler (Waters, UK) and a 2487  absorbance detector 
(Waters, UK).  The column used was a reversed-phase C18 (250 x 4.6 mm).  UV-
photodiode array detection was performed at 240 nm.  The mobile phase consisted 
of acetonitrile: PBS buffer (36:64 % v/v) at a flow rate of 1.4 ml/min.  Final pH of the 
mobile phase was adjusted to 7.5 by diluted hydrochloric acid.  Column temperature 
was set to 28°C and 10 μl of samples was injected to the HPLC system.  The 
method was proved to be ‘fit for purpose’ in the concentration range of 1-0.01 mg/ml 
(Section 2.4.2). 
 
3.3.5. Data analysis and statistics 
 
All data was expressed as mean ± standard deviation (S.D.)  Statistical analysis was 
performed in SPSS, version 16.0, using either student t-test or an analysis of 








3.4.1. Characteristics of the nanoparticulate systems 
 
The blank PVA NSs had a mean diameter of ca. 210 nm and a very low 
polydispersity index of 0.08 ± 0.01 indicating a very narrow particle size distribution 
(Table 3.1).  They had a zeta potential of - 7.46 ± 1.18 mV (n = 3).  The plots of 
hydrodynamic diameter versus concentration showed a linear profile and a a 
relatively shallow gradient (Figure 3.2).  The PVA NCs were significantly smaller than 
the NSs with a mean diameter of ca. 150 nm, a polydispersity index of 0.14 ± 0.02 
and a monomodal size distribution (Figure 3.3).  The NCs exhibited a negative 
charge (- 7.43 ± 2.34 mV).  The cryo-EM images demonstrated that the particles had 
a spherical morphology and their volume diameter observed visually correlated well 
with the hydrodynamic size measured by PCS (Figure 3.4).  The recovery of PVA 
nanospheres was significantly higher (60.2 ± 5.4 %) than the nanocapsules (24.6 ± 
1.8 %), (Table 3.1).  Both nanoparticle formulations exhibited good physical stability 
and no significant changes (p > 0.05, ANOVA) to the nanoparticle size occurred after 























Figure 3.2.  A representative nanoparticle hydrodynamic diameter versus plot used 
to determine the absolute diameter of the PVA nanospheres (A) and nanocapsules 
(B)  (all data are represented as mean ± sd, n = 3) 
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208.7 ± 7.9 
 









Zeta potential (mV) 
 
 
- 7.46 ± 1.18 
 
 






60.2 ± 5.4 
 
24.6 ± 1.8 
 
Table 3.1.  The particle size, polydispersity index (PI), zeta potential and yield of 
blank PVA nanospheres (NS) and nanocapsules (NC).  (all data are represented as 






3.4.2. Rifampicin loading 
With the increase of rifampicin input from 5 to 25 mg, the drug content in the NS 
significantly increased from 06.5 ± 0.5 to 22.9 ± 0.5 % (table 3.2). As the loading of 
rifampicin increased the NS encapsulation efficiency slightly reduced from 38.6 ± 1.1 
to 29.3 ± 0.7 %.  The drug recovery was significantly lower with low drug input and 
this correlated with the presence of drug crystal nanosuspensions with a high drug 
loading.  The size of rifampicin-loaded NS ranged from 200 nm to 226 nm.  As the 
drug input increases there was a slight increase from 209 m to 217 nm.  The 







When the NC drug input increased from 5 to 25 mg, the drug content of the 
nanocapsules increased from 2.1 ± 0.1 to 8.1 ± 0.5 % (Table 3.2).  Rifampicin-
loaded NC were significantly smaller than than the placebo samples (p < 0.05, 
ANOVA).  However, as the rifampicin input increase there was not a significant 
increase (p > 0.05) (Table 3.2).  The polydispersity index of the rifampicin-loaded NC 
ranged between 0.1 and 0.25 but the size distribution was consistently monomodal. 
 



























06.5 ± 0.5 
11.7 ± 0.6 
22.9 ± 0.5 
- 
2.1 ± 0.1 
3.6 ± 0.1 
8.1 ± 0.5 
38.6 ± 1.1 
34.5 ± 0.5 
29.3 ± 0.7 
- 
39.3 ± 0.5 
35.5 ± 0.8 
32.3 ± 0.3 
73.6 ± 3.1 
81.1 ± 0.8 
86.2 ± 1.5 
- 
72.6 ± 0.9 
78.5 ± 2.2 
85.7 ± 7.4 
209.2 ± 4.7 
212.1 ± 5.2 
217.3 ± 9.9 
- 
134.6 ± 4.1 
132.1 ± 7.7 
130.4 ± 5.3 
 
Table 3.2.  Rifampicin loading in PVA nanospheres (NS) and PVA nanocapsules 
(NC).  The drug content, encapsulation efficiency, rifampicin recovery and particle 
size were presented.  Each formulation was manufactured in triplicate, (values 









































212.5 ± 7.5 
 
 
230.3 ± 10.1 
 
 
234.0 ± 8.5 
 
211.3 ± 6.7 
 
217.2 ± 3.4 
 




228.5 ± 6.2 
 
 
231.6 ± 5.6 
 
 
243.7 ± 12.7 
 
 
215.7 ± 3.5 
 
227.1 ± 4.8 
 





146 ± 8.7 
 
 
148.5 ± 5.01 
 
151.3 ± 5.4 
 
 
154.8 ± 7.5 
 
155.9 ± 3.8 
 




137.1 ± 1.9 
 
135.5 ± 3.2 
 
132.8 ± 14.9 
 
128.9 ± 8.1 
 
137.1 ± 7.6 
 
136.4 ± 15.5 
 
Table 3.3. The stability of the nanoparticulate systems: blank PVA nanospheres (B-
NS), rifampicin-loaded PVA nanospheres (NS-3), blank nanocapsules (B-NC) and 
Rifampicin-loaded nanocapsules (NC-3) over 7 d.  (values represent mean ± sd, n = 
3). 
 
3.4.3. In vitro rifampicin release  
The in vitro release of the two rifampicin-loaded nanocarriers, measured as the 
percentage of drug remaining in the nanosystems, showed that the two PVA 
nanocarriers exhibited different behaviours at different pHs (Figures 3.5 and 3.6).  
The initial burst release was prominent for the particles during the first 2 h. This was 
followed by gradual reduction of release.  At pH 7.4, approximately 10 % and 25 % 
of drug was released in the first 2 h, for NS and NC, respectively. At pH 4.2, 
approximately 35 % and 25 % of drug was released in the first 2 h, for NS and NC, 
respectively.  The release rate gradually decreased for both particles at pH 7.4 with 
the amount of drug released reaching 35 % (NS) and 40 % (NC) at 48 hr.  The same 
pattern was observed at pH 4.2 with 75 % drug released from NS and 80 % from the 
NC (Figure 3.4).  Resuspending the nanoparticles in glycine-NaOH: ethanol mixture 





Approximately 40 % and 60 % of drug was released in the first 6 h, for NS and NC, 





Figure 3.5. Release profile of rifampicin from the PVA Nanospheres (A) and PVA 
Nanocapsules (B) in PBS buffer (pH 7.4) (diamond) and at citrate buffer (pH 4.2) 













































































































Figure 3.6. Release profile of rifampicin from the PVA nanospheres (A) and PVA 
nanocapsules (B) at glycine-NaOH (pH 10) (triangle) and at glycine-NaOH buffer (pH 










































































































It was previously demonstrated that rifampicin was prone to degradation in aqueous 
solutions.  This could be one of the reasons for the variable bioavailability of the drug 
and the sub-therapeutic concentrations reaching the lung after oral administration.  
Therefore, the aim of this Chapter was to encapsulate rifampicin into new polymeric 
nanocarriers that can protect the drug from degradation after administration and 
reduce its toxicity. PVA was selected for the preparation of the nanocarriers because 
of its biocompability and its potential to control drug release.  
PVA nanocarriers were manufactured using solvent displacement method which was 
previously used successfully to prepare polymeric nanoparticles in an efficient and 
reproducible manner (Thioune et al., 1997 and Chorny et al., 2002).  This method, 
first developed by Fessi et al., (1989) has the advantages of being a straightforward 
technique, rapid and easy to perform.  In addition, extended shearing, sonication or 
very high temperatures are not required.  Moreover, the use of potentially toxic 
components (including chlorinated solvents) may be minimised or avoided in this 
procedure (Fessi et al., 1989).  With appropriate modifications, this method was 
suitable for producing both vesicle and matrix type nanoparticles, NSs and NC, 
respectively. 
The size and recovery yields of the nanoparticles fabricated were highly 
reproducible.  The particle size distribution measured by PCS demonstrated a 
homogeneous population characterised by a narrow size distribution.  The theory of 
PCS is based on the “Brownian motion” that is caused by elastic impacts between 





However, the light-scattering process always presupposes that the scattered light 
reaches the detector without any further interference by other particles.  Such 
multiple scattering can only be avoided by carrying out the analysis at the highest 
possible dilution where, unfortunately, signal strength is likely to be very weak and 
there will be a low signal-to-noise ratio.  For that reason, it was important to plot the 
hydrodynamic particle size against the concentration and the intercept (zero 
concentration) was taken as the absolute diameter.  These plots showed a good 
linearity and a shallow but significant gradient.  This can occur as a result of the 
interference of the high molecular weight stabilizing polymer with light scattering.  
Cryo-EM was also to verify the results obtained by PCS.  The nanoparticle size as 
observed by Cryo-EM correlated well with the hydrodynamic size measured by PCS.  
Cryo-EM analysis also showed that the nanoparticles were spherical in shape. 
The encapsulation efficiency of the two particles using PVA was comparatively high.  
Ismaeili et al., (2007) investigated the effects of a number of parameters on the 
encapsulation efficiency of rifampicin in PLGA nanoparticles such as: concentration 
of polymer in aqueous phase, solvent nature, and saturation of the outer phase with 
drug (Esmaeili et al., 2007). However, 3.2% was the highest encapsulation efficiency 
achieved in their study.  This was due to the ionisation of rifampicin and its diffusion 
to the aqueous phase.  In order to increase the amount of drug that could be 
incorporated into nanoparticles, an increase of the theoretical loading (amount of 
drug used in the formulation) was used along with a modification of the pH 
(Govender et al., 1999; Ueda and Kreter., 1997; Zhao et al., 2010).  The lowest 
degree of ionisation of rifampicin is achieved at pH 4.8 and the diffusion of the drug 





phase was maintained at 4.8 to suppress the diffusion of the drug to the external 
phase and improve encapsulation efficiency.   
The hypothesis behind loading rifampicin into the nanocapsules was that the higher 
affinity of rifampicin to the benzyl benzoate would result in the drug being retained in 
the oily droplets during their formation instead of diffusing out with the organic 
solvents.  However, due to the complexity of the system, significant amounts of 
rifampicin were bound to the excess phospholipids and only 32 % of the drug was 
retained in the nanodroplets. 
The in vitro release of the two rifampicin-loaded nanocarriers showed that the two 
PVA nanocarriers exhibited different behaviours at different pHs.  For all 
formulations, there was an initial burst release during the first 2 h followed by a 
gradual reduction of release.  The initial burst could be due to the diffusional release 
of rifampicin distributed at or just beneath the surface of the nanoparticles.  
Rifampicin release from the nanoparticles happens either by diffusion through the 
polymer barriers or by the erosion of the polymer.   When the pH was altered to 4.2 
or 10, there was a significant increase in the drug release.  The mechanism of 
polymer hydrolysis at low pH is unclear. At high pH, and in the presence of ethanol, 
the mechanism is postulated to involve the adsorption of the alkali catalyst onto the 
free hydroxyl groups resulting in the hydrolysis of the acetate groups of the polymer, 
also known as alcoholysis (Chana et al., 2008., Katsurya et al., 2001., Moritani et al., 
1977).  The release profiles of the drug from PVA nanoparticles are different from the 
ones reported for PLGA nanoparticles which makes PVA can an interesting material 






The methodology allowed the rapid and reproducible formation of new PVA NSs and 
NCs.  The successful encapsulation of first line anti-TB drug, rifampicin, into these 
nanocarriers would protect the drug from degradation and reduce the associated 
side effects (such hepatotoxicity) after administration.  More interestingly, the PVA 
nanocarriers released rifampicin at different rates in different media.  The ability of 
these vectors to deliver the drug to the lung and release it in a controlled manner 
would solve a number of anti-TB therapy issues.  
Macrophages are known to provide a niche for Mycobacterium tuberculosis.  The 
ability of these nanocarriers to deliver the drug to these infectious reservoirs would 
reduce the reccurence of the infection.  In the next chapter, the uptake of these 
carriers by macrophage-like cell line will be evaluated.  The association of rifampicin 
with these cells will be monitored using the PVA nanocarriers and drug solutions.  













Uptake of PVA nanoparticles by the 







TB is transmitted by inhalation of Mycobacterium tuberculosis in fresh airborne 
droplets emitted by the coughing pulmonary TB patient (Pratt et al., 2005).  Upon 
deposition in the alveolus, the tubercle bacilli are taken up and destroyed by AMs.  
However, in some instances, virulent bacilli continue to grow within the AMs, 
eventually releasing additional bacilli until, in an immune-competent host, cell-
mediated immunity develops (Dannenberg, 1993; Ferrari et al., 1999). At this time 
granulomas are formed and growth of the virulent bacilli is inhibited.  However, the 
mycobacterium can persist for decades in a dormant state inside in the granulomas 
for years, either inside macrophages or in the central necrotic core of the lesions 
(Figure 1.2) (Ulrichs et al., 2006).  Reactivation of these latent organisms can also 
lead to post-primary disease, even in persons who successfully fought their initial 
battle against TB (section 1.1).  
In the current TB therapy, high drug doses are required to be administered as only a 
small fraction of the total dose reaches the lungs after oral administration.  The 
recurrence of the infection could be related to the insufficient drug concentrations 
achieved in macrophages and in granulomas for full eradication of dormant 
mycobacteria.  Moreover, the granulomas are believed to be isolated from the 
outside environment due to a thick, calcified stratum surrounding them.  The inability 
of drugs to penetrate these lesions could be another factor in the failure of current 
therapy to kill the virulent bacilli residing these lesions.  Recently, Takaki et al., 
(2011) monitored the movement of individual macrophages from a particular 





recruit other macrophages to create new granulomas, often at sites distant from the 
original (Takati et al., 2011).   
In the previous chapter, rifampicin was encapsulated in PVA nanoparticles.  The 
ability of these PVA nanocarriers to deliver the drug to macrophages would not only 
kill the intracellular mycobacteria in these cells, but it would also have the potential to 
target the bacilli occupying the granulomatous lesions.  Therefore, the aim of this 
study was to investigate the uptake of PVA nanoparticles by a macrophage-like cell 
line, J774A.1.  This model was chosen because it is a standard cell line used in 
phagocytosis studies that faithfully mimics many aspects of macrophage function.   
The potential of a macrophage-targeting strategy using nanoparticle-encapsulated 
TB drugs is supported by in vitro data from a number of studies. For example, 
incorporation of isoniazid and streptomycin in poly(butyl cyanoacrylate) PBCA 
nanoparticles not only increased intracellular accumulation (or association) of these 
drugs in the cultivated human blood monocytes but also produced enhanced 
antimicrobial activity of these agents against intracellular M. tuberculosis compared 
with their activity in extracellular fluid (Anisimova et al., 2000).  Kisich et al. (2007) 
showed that the encapsulation of moxifloxacin in PBCA nanoparticles resulted in a 
pronounced increase in the intracellular concentration of infected macrophages.  In 
addition, encapsulated moxifloxacin was more effective than the free form to kill 
intracellular bacilli (Kisich et al., 2007).  However, the non-biodegradability of the 
polymer PBCA employed in their study constitute a main limitation.  More, recently, 
Ohashi et al. (2009) demonstrated that the encapsulation of rifampicin in PLGA 





lungs as compared to rifampicin-containing PLGA microparticles (Ohashi et al., 
2009).    
The physicochemical characteristics of particles and media properties have a 
significant effect on the transport of nanoparticles to cells in vitro (Limbach et al., 
2005).  The dynamics that dictate particle transport include: diffusion, gravitational 
settling and agglomeration.  It is hypothesized that cells exposed to a nanoparticle 
suspension in vitro, will not receive a drug payload nor will be able to interact with 
the nanoparticles (e.g. exhibit internalization or toxicity-related responses) unless the 
nanoparticle comes into physical contact with the cell monolayer through the 
processes of gravitational settling and diffusion.  Therefore, it is proposed that a new 
dose metric, the cellular dose, be used to describe the number or surface area of 
nanoparticles that reaches the cell layer during a given experimental duration (e.g. 
number/cm2, surface area/cm2; Equation 4.1).  The advantage of the cellular dose 
compared to the nominal dose (defined as the mass, number or particle surface area 
per total volume of suspension medium added to the cells) is that it takes into 
account not only the nominal concentration of particles added to the in vitro 
experiment, but also the exposure time, and is therefore a more description metric. 
Gravitational settling is the result of opposing forces: gravity, drag and buoyancy.  
Drag, which is due to viscous forces of the fluid on the moving particle, is a function 
of particle diameter, fluid viscosity and particle velocity.  Buoyancy (force exerted by 
the displaced fluid) is a function of particle diameter and the density of the medium 
(Bird et al., 1960).  The gravitational force is a function of mass (particle diameter 





dependent on particle size and density.  The terminal settling velocity can be 
calculated from Stoke’s law as: 
 
    






Where Vs is the particle’s settling velocity (m s
-1); g is the gravitational acceleration 
(m s-2); ρs is the mass density of the particles (kg m
-3); ρm is the mass density of the 
fluid (kg m-3);   is the fluid's viscosity (kg m-1 s-1) and r is the radius of the particle 
(m). 
By inserting values for the incubation time, estimated particle density, density and 
viscosity of the cell culture medium at 37°C, and the radius of the particle (based on 
the measured hydrodynamic diameter in cell culture medium), the maximum 
sedimentation distance can be calculated.  Assuming that this value (converted from 
m to μm for ease of understanding) represents the height of a suspension-filled 
cylinder directly above the cell monolayer in which all particles suspended therein 
will sediment onto the cell surface within the duration of the experiment, it is possible 
to estimate the number of particles that will be present within this particular volume 






Figure 4.1. Schematic representation of nanoparticle distribution in cell culture 
model at t=0. 
Agglomeration is the combination of individual particles into larger masses due to 
attractive forces or chemical binding (Maeakin, 1988).  Agglomeration shifts the size 
distribution of particles from that of the primary particles to a distribution with larger 
mean and usually greater dispersity.  Agglomerates have a higher mass and volume 
than individual particles they are composed of and have correspondingly higher 
gravitational and buoyant forces acting on them.   
Diffusion is the spontaneous, passive movement of particles from high chemical 
potential areas to low chemical potential ones.  When a suspension is applied to an 
adherent cell culture, a concentration gradient, which drives diffusional transport of 
these particles, may be created when particles adhere to or are taken up by cells.  
Since rates of diffusional transport are a function of particle size and the viscosity of 
the media, smaller particles tend to diffuse more rapidly than larger particles.  








    
   
                                 (4.2) 
Where c is the particle’s concentration (kg m-3); D is the diffusion coefficient (m2 s-1); 
t is the time (s) and z is the spatial coordinate (from bottom to top of the culture well) 
(m). 
To calculate the diffusional component of the cellular dose, the assumption must be 
made that particles will diffuse from the liquid toward the cells in one dimension (top 
to bottom of the culture well). Although this assumption is not representative of true 
vectorial movement in a suspension, the approximation has been used by other 
authors (Teeguard and Limbach).  The diffusion coefficient D of a small particle can 
be derived using the Stokes-Einstein (equation 4.3). 





    (Equation 4.3) 
Where R is the gas constant (8.314 J/K/mol); T is temperature (K); N is Avogadro's 
number; µ is the solution viscosity (kg/m/sec) and d is the particle diameter (m).  
Assuming that at  t+Δt the concentration at any other given position z (z = ∞)would 
be equal to the initial concentration of particles Cinitial (Figure 4.2).   
t=0, all z: C=Cinitial 
t>0, z=0: C=0 





The number of particles reaching the cells can be determined by calculating the flux 
of particles diffusing towards the cell layer j (kg m-2 s-1) using Fick’s law: 
   
 
  
                   (4.4) 




Figure 4.2.  Schematic representation of particle distribution in cell culture model at 
t=0 and t= t+Δt. 
 
The net impact of these processes has been ignored by studies relying on simple 
metrics such as nominal media concentration or nominal number of particles 
(Chitrani et al., 2006; Desai et al., 1996; He et al., 2010; Schwarze et al., 2007; 
Zauner et al., 2001). This can obscure the relationships between response and 
particle characteristics, leading to misleading conclusions regarding the dynamics of 





size, on the uptake, particles of different sizes should be delivered to a standardised 
cell culture system at the same dose of a specific number of particles or particle 
surface area.  This allows the examination of particle size as a determinant of 
response when other variables are controlled. 
The aim of this study was to investigate the uptake of PVA nanoparticles by a murine 
macrophage-like cell line, J774A.1 cells.  The objectives were to: 
 Evaluate any toxicity of the PVA nanocarriers towards the J774A.1 cells. 
 Verify the stability of PVA nanoparticles in cell culture media. 
 Establish assays for the quantification of proteins recovered from cells and to 
quantify rifampicin in cell lysate. 
 Compare the association of rifampicin with the J774 macrophage-like cell line 
after incubation with PVA nanospheres, nanocapsules and free drug in 
solution. 
 Develop a model to determine the delivered doses (according to rate of 







Cell culture reagents including Dulbecco’s Modified Eagle Medium with phenol red 
(Lonza) cell culture medium, Fetal Bovine Serum (FBS), L-Glutamine, Sodium 
pyruvate, Sodium Dodecyl sulphate and HEPES were purchased from Sigma-Aldrich 









4.3.1. Preparation of nanoparticle suspensions 
PVA NS and NC (NS-3 and NC-3, Table 3.2) were manufactured according to 
section 3.3.1.  The 30 ml  nanosuspension batches produced were concentrated to 1 
ml by an ultrafiltration/centrifugation technique using 15 ml centrifugal filter devices 
(Amicon ultra 15®) with MWCF (molecular weight cut-off) of 100 kDA (Fisher 
Scientific, UK) at 3000×g  for 1.  
4.3.2. Particle size and colloidal stability of PVA nanocarriers in 
biological fluids 
The particle size and colloidal stability physical stability of the nanoparticle 
suspension were assessed in cell culture medium using photon correlation 
spectroscopy at predetermined time points (t=0 and 6 h).  Nanoparticle suspensions 
were measured at the different concentrations used in this study as test solutions. 
The hydrodynamic diameter of particles was determined for each batch in triplicate. 
 
4.3.3. Cell culture methodology 
The J774A.1 cell line was obtained from Dr H. Collins ( Department of Infectious 









4.3.3.1. Cell maintenance 
Cells were grown in 162 cm2 cell culture flasks using cell culture medium (DMEM 
suplemented with 10% v/v FBS, 1% v/v L-glutamine, 1% v/v Sodium pyruvate and 1 
% v/v HEPES.  Cells were grown in a humidified environment in an atmosphere of 
5% CO2 at 37
oC.  Medium was changed twice a week.  After aspiration of old media, 
20 ml of warmed fresh medium was added to cell layers. 
 
4.3.3.2. Cell passage 
Cells were subcultured when 90-100 % confluency was reached, approximately once 
a week.  This was confirmed by examining the flask surface under light microscope.  
After aspiration of old medium, cells were detached by scraping cell layers from the 
surface of flask in 1 ml of warmed fresh cell culture medium.  After repeat pippeting 
to generate a suspension of single cells, the cell suspension was divided into new 
culture flasks (at a split ratio of 1: 5) and 20 ml of cell culture medium was added to 
each flask. 
 
4.3.3.3. Cell counting 
After detachment of cells, 20 µl of the cell suspension was removed and mixed with 
20 µl tryptan blue.  This was placed on the haemocytometer after affixation of cover 
slip.  Six large squares from each of the top and bottom sections were counted at 















Where N is the mean number of cells per large square; d factor  is the dilution factor of 
cell suspension and V is the volume of square 
 
4.3.4. Biocompatibility of PVA nanoparticles with J774A.1 
4.3.4.1. Metabolic activity test (MTT) 
The biocompatibility of nanoparticle formulations was determined in J774A.1 cells in 
96-well plates using an MTT assay (Mosman, 1983).  The MTT is a colourimetric 
method for the determination of cell viability based on the reduction of the yellow 
tetrazolium salt MTT to a purple formazan dye by mitochondrial sccinate 
dehydrogenase in viable cells. 
Cells were seeded in 96-well plates at a density of 5 x 104 cells/well in 100 µl of cell 
culture medium and used in experiments after 12 h.  Concentrated nanosuspensions 
prepared in section 4.3.1 were diluted with cell culture medium (1 in 4, 8, 16, 32, 64, 
128, 256 and 512) .  To initiate the assay, the medium was removed and 100 µl of 
each test suspension was added to the cells and incubated for 6 h.  Cell culture 
medium was used as negative control and cell culture medium supplemented with 
2% SDS was used as a positive control.  After removal of solutions, the cells were 
incubated with 50 µl of MTT (0.5 mg/ml in PBS) for 4 h.  Afterwards, 100 µl of 10% 
SDS in was added to solubilise the water insoluble formazan crystals overnight.  
Upon complete solubilisation of the crystals, the absorbance of each sample was 
measured at 570 nm and corrected for background absorbance at 650 nm.  The cell 
viability was calculated as the ratio of treated cells and the untreated cells.  Each 






4.3.4.2. Determination of monolayer protein content using the 
Bradford assay 
Protein concentrations in cell monolayer can provide an indication of the total 
number of adherent cells remaining on the plate after the incubation period.  
Changes to the total protein concentration in nanoparticle or drug treated cells, as 
compared to non-treated cells, can provide information on cell detachement as 
caused by 1) excessive particle uptake or 2) cell death.  Total monolayer protein 
concentration was determined by a modified Bradford assay using BSA as the 
standard (Bradford, 1976).  Standard solutions containing 1000, 750, 500, 250, 125 
and 25 µg/ml of BSA were prepared by diluting the BSA stock solution (2000 µl/ml) 
in water.  Each standard (10 µl) was transferred into a microplate and 300 µl of the 
coomassie plus reagent (Contains coomassie G-250 dye) was added. The solutions 
were mixed in a plate shaker for 30 seconds and incubated at room temperature for 
10 minutes.  The absorbance was measured at 595 nm with a plate reader.  After 
substracting the average absorbance for the blank (water) from the measurements of 
all standards, a calibration curve was created by plotting the average blank-corrected 
absorbance versus concentration.  The linearity was evaluated by linear regression 
analysis, which was calculated by the least square regression method.  Accuracy 

















Where T is the theoretical concentration of analyte and A is the actual concentration 
of analyte.  To measure the quantity of proteins recovered from cell homogenates, 
10 µl of cell lysate was diluted with 300 µl of the dye and the absorbance was 
measured at 595 nm with a plate reader.  The calibration curve of BSA in water 
displayed a good linearity over the concentration range of 25-1000 µg/ml, with 
correlation coefficient of >0.99 (Figure 4.3).  The recovery values ranged between 




Figure 4.3.  Calibration curve for the Bradford assay for BSA.  Data represent mean 
± sd, n=3 calibration curves (each each calibration curve having 3 analyses at each 
concentration). 
 
4.3.5. Cell association and uptake of PVA nanoparticles by J774A.1 cells 
4.3.5.1. Rifampicin quantification in the presence of cell 
homogenate 
Cell homogenates were spiked with different concentrations of rifampicin (250, 100, 
40, 10, 4 and 4 µg) and centrifuged at 10,000 g for 10 minutes.  The supernatants 
























were filtered and the amount of drug was quantified using HPLC developed in 
section 2.3.2.  The calibration curve of rifampicin in cell lysate was compared to the 
one of rifampicin in water: ethanol mixture (50: 50). 
 
 
4.3.5.2. Rifampicin uptake by J774A.1 cells 
Cells were seeded in 24-well plates at a density of 5 x 105  cells/well in 500 µl of cell 
culture medium and used in experiments after 12 h.  Upon reaching confluence, cell 
uptake of nanoparticles was initiated by exchanging cell culture medium with 500 µL 
of specified nanoparticle suspension and incubating the cells at 37oC for 6 h. PVA 
nanoparticles containing 100, 200, 500 and 1000 µg /ml of RIF were suspended in 
the medium and were added separately into the well containing cells. Control 
rifampicin solutions contained 100, 200, 500 and 1000 µg /ml of drug.  The 
experiment was terminated by washing the cell monolayer three times with 
phosphate-buffered saline (PBS, pH 7.4) to eliminate excess particles which were 
not strongly associated to the cells (i.e. either internalized or adhering to cells).  The 
cell membrane was permeabilized using probe sonication to expose the internalized 
nanoparticles for quantitative measurement. Cell-associated nanoparticles were 
dissolved in ethanol and quantified by analyzing the cell lysate using HPLC.  The 
quantification method was shown to be “fit for purpose” in the presence of cell 







4.3.6. The predicted cellular dose 
The predicted cellular dose was determined by combining the mumber of particles 
reaching the cell monolayer after 6h via both sedimentation and diffusion (Equation 
4.7) 
               
                                                  
                              
                 (4.7) 
* Taking agglomeration behavior into consideration 
Number of particles reaching the cells via sedimentation and diffusion were 
calculated using equations 4.1 to 4.4. 
 
Note: This particokinetic model for calculating the predicted cellular dose was 
develop by Abhinav Kumar (Pharmaceutical Research Science division, King’s 
College London, Uk) as part of his PhD project and was used in this work with his 
permission.  
4.3.7. Data analysis and statistics 
 
All data was expressed as mean ± standard deviation (S.D.)  Statistical analysis was 
performed in SPSS, version 16.0, using either student t-test or an analysis of 









4.4.1. Stability of PVA-VAc nanocarriers in biological fluids 
The rifampicin-loaded PVA nanospheres and nanocapsules showed size increases 
at different concentrations after incubation in cell culture medium at 37oC over 6 h 
(table 4.1).  As it can be seen for both formulations; the particle size increases both 
over time and as the concentration increases.  The increase for the nanocapsules 






















211.7 ± 5.4 
 
257.1 ± 14.8 
 
141.5 ± 7.7 
 
281.2 ± 15.7 
200 225.4 ± 7.1 268.2 ± 18.1 144.6 ± 3.8 308.7 ± 25.3 
500 220.5 ± 11.7 274.3 ± 21.3 152.5 ± 5.7 325.1 ± 31.7 
1000 224.4 ± 9.4 288.2 ± 10.9 151.9 ± 11.7 345.9 ± 19.8 
 
Table 4.1.  The stability of rifampicin-loaded PVA nanospheres and rifampicin-
















4.4.2. Biocompatibility of PVA nanoparticles with J774A.1 
The metabolic activity of the PVA nanoparticles was higher than 80% at all 
concentrations for the rifampicin loaded nanoparticles lower than 10 mg/ml (Figure 
4.4 and 4.5).  As the nanoparticle concentration increased the viability decreased 




Figure 4.4.  Viability of J774A.1 cells after incubation with blank PVA nanospheres 
(diamond) and Blank PVA nanocapsules (squares) and for 6 h at different 




























Figure 4.5.  Viability of J774A.1 cells after incubation with rifampicin-loaded 
nanospheres (diamond)  and rifampicin-loaded nanocapsules (squares) for 6 h at 
different concentrations (n=6).  
 
 
The amount of protein recovered from the J774 cells after 6 h incubation with 
rifampicin-loaded nanospheres, Rifampicin-loaded nanocapsules and free rifampicin 
varied (Fig 4.6).  As it can be seen, the amount of protein recovered in the 
homogenate decreased as the amount of nanoparticles presented in the test solution 
or suspension increased.  There was also significant difference between the 
amounts of protein recovered after exposure to nanospheres and nanocapsules (p < 
0.05, ANOVA).  For example, when exposed to PVA nanoparticles containing 500 µg 
of rifampicin, the amount of proteins recovered was 404.3 ± 81.7 and 201.8 ± 39.1 
µg, for nanospheres and nanocapsules, respectively.  Statistical analysis also show 
that drug encapsulation in nanospheres significantly increase cell recovery 


























Figure 4.6.  The amount of protein recovered from the untreated J774A.1 cells after 
6h incubation with rifampicin-loaded nanospheres (black), rifampicin-loaded 
nanocapsules (grey), free rifampicin (white) and untreated cells (dark grey) (n=3). 
 
 
4.4.3. Rifampicin quantification in the presence of cell lysate 
In order to rule out interference by cell lysate components, the rifampicin extraction 
and quantification procedure was validated by spiking known amounts of rifampicin 
into representative volumes of cell lysate and evaluating recovery and signal 
intensity using the HPLC method described in  Chapter 2.3.2.  The calibration curve 
of rifampicin in cell lysate displayed excellent linearity over the concentration range 
of 0.1-0.001 mg/ml, with correlation coefficient of >0.999 for the peak area 
calculations (Figure 4.7).  The calculated LOD value was 0.8 µg/ml while the LOQ 
































% (n=3).  The calibration curve of rifampicin in ethanol: water (50: 50) mixture is 






Figure 4.7.  Calibration curve for HPLC assay for Rifampicin in Ethanol: water 
(50:50) mixture (Square) and Cell lysate (Diamond).  Data represent mean ± sd, n=3 




4.4.4. Delivery of Rifampicin to J774 cells 
The amount of rifampicin associated with the J774A.1 increased as the amount of 
drug administered increased (Figure 4.8).  As the drug input increases from 50 to 
500 µg, the amount of drug accumulating in the cells increases from 3.9 to 10.2 µg 
and from 3.8 to 7.5 µg for PVA nanospheres and nanocapsules, respectively.  In 
y = 11769x - 6.6861
R² = 0.9999



















contrast, the amount of free rifampicin accumulated in the cells was significantly 
lower (p < 0.05, ANOVA).  The increase was only from 2.7 to 3.3 µg over the 6 h 
incubation time. 
 
Since the Bradford assay results showed that the mass of proteins recovered was 
different for the three formulations (Fig 4.9), the uptake results were normalised and 
presented as mass of drug per mass of proteins (Figure 4.6).  The same trend was 
observed as in figure 4.6.  The amount of the dug associated with the cells was 
significantly higher for the PVA nanocarriers than the free drug (p < 0.05, ANOVA). 
However, the PVA nanocapsules were shown to be more efficient in terms of 
delivering the drug to the cells.  When the cells were incubated with the same dose 
of drug e.g 1000 µg, the drug concentration reached 0.6, 0.5 and and 0.06 µg/ µg 
(drug/protein) for the NC, NS and free drug, respectively (Figure 4.9). 
 
 
Figure 4.8.  The amount of rifampicin accumulated inside the J774A.1 cells after 6h 
incubation with rifampicin-loaded nanospheres (Black), rifampicin-loaded 






































Figure 4.9.  The amount of rifampicin per mass of protein recovered from J774A.1 
cells after 6h incubation with rifampicin-loaded nanospheres (black), rifampicin-





4.4.5. The predicted cellular dose 
Particokinetics calculations show that the percentage of nanoparticles reaching the 
cell monolayers was between 13.6 and 19.6 % (Table 4.2).  It can also be seen that 
the predicted dose for the PVA nanocapsules was approximately double the 















































































































































































Table 4.2.  The nominal and predicted dose of rifampicin-loaded nanospheres (NS) 


















The aim of this study was to investigate the uptake of PVA nanoparticles by a 
macrophage-like cell line, J774A.1.  This model was chosen because it is a standard cell 
line used in phagocytosis studies that faithfully mimics many aspects of macrophage 
function.  In this regard, a study using mouse macrophage cell line J774A.1 showed 
that certain combinations of antimicrobial agents are able to kill the Mycobacterium 
avium complex (MAC) inside macrophages and suggested that this cell line could be 
used as a model for screening of drugs for intracellular activity against MAC (Yajko 
et al, 1989).  As a test of the validity of this model, alveolar macrophages isolated 
from the bronchoalveolar lavages of 36 patients were used for the same experiment.  
The good agreement between the alveolar macrophages results and those obtained 
with J774A.1 cells gave further evidence that mouse macrophage continuous cell 
line J774A.1 is a valid alternative to the use of alveolar macrophages to screen 
antimicrobial agents for intracellular activity against MAC (Yajko et al., 1991). 
 
The cell viability was measured by quantification of mitochondrial dehydrogenase 
activity.  The blank and rifampicin-loaded PVA nanoparticles showed negligible 
cytotoxicity in the J774A.1 cells after a 6h incubation at concentrations of 10 mg/ml 
or lower.  Lherm et al., (1992) observed a time-dependent increase in cytotoxicity 
after incubating different types of poly (alkyl cyanoacrylate) nanoparticles with L929 
fibroblasts (Lherm et al., 1992). This phenomenon was found to be related to the 
degradation products of the polymer.  In our study, the low toxicity data could be 





Bradford assay was employed in this study as a cell recovery-indicating assay.  After 
incubation with the PVA nanocarriers the adherent cells were lysed and proteins 
released were quantified to determine cell recovery.  This assay demonstrated that 
there was a significant decrease in cell recovery after exposure to the drug (p< 0.05).  
The high toxicity of cells in the presence of free rifampicin has been demonstrated by 
a number of studies (Barrow et al., 1998; Kumar et al., 2006).  Barrow et al., (1998) 
demonstrated that the incubation of MM6 human monocytic cells with rifampicin 
solution (2 µg/ml) for 7 days resulted in  viability of 42 %.  In another study, Kumar et 
al., (2006) showed that rifampicin solution was toxic to VERO cells as only 50% of 
cells were viable after 72 h exposure.  In our study, it was shown the encapsulation 
of rifampicin in PVA NS was shown to significantly reduce the toxicity of rifampicin 
for the J774A.1 cells (p < 0.05). 
 
Loading rifampicin in the PVA nanocarriers dramatically enhanced the amount of 
drug associated with the cells.  The amount of rifampicin imported into macrophages 
by drug-loaded nanoparticles, containing 1000 µg/ml of drug, was twice (NC) or 
three times (NS) greater than that attained with rifampicin solution.  Similar results 
have been reported by Skidan et al. (2003) using rifampicin-loaded PBCA 
nanoparticles.  The drug levels in alveolar macrophages 2-3 fold after incubation with 
with rifampicin-loaded nanoparticles in comparison to the free drug (Skidan et al., 
2003).  However, the polymer PBCA used in their study to produce the nanoparticles 
is non-biodegradable which limits the potential to use these particles as delivery 
systems.  In addition, PBCA nanoparticles have been shown to exhibit a cytotoxic 





demonstrated increased efficacy of nano-encapsulated drug in macrophage-infected 
models (Forestier et al., 1992; Balland et al., 1996 and pinto-Alphadary et al., 1994).  
It was suggested that the efficacy of nanotargeted therapeutic agents to 
macrophages, during bacterial infections, can be attributable to the maintenance of 
higher drug levels inside these cells. 
The enhanced accumulation of encapsulated rifampicin relative to free form shows 
that the encapsulation allows entry of rifampicin into the cells using an additional 
cellular internalization process, presumably phagocytosis or endocytosis.  Vauthier 
et al. (2003) showed that that the uptake of nanoparticles by J774 macrophages 
occurs via an endocytocis process, after which the particles end up in the lysosomal 
compartment where they are degraded (Vauthier et al., 2003).  In another study, 
wheat germ agglutinin-conjugated PLGA nanoparticles were shown to be taken up 
up by A549 cells by a receptor-mediated, caveola-dependant endocytic pathway (Mo 
and Lim, 2004) 
 
Using the developed particokinetics model to calculate the predicted dose it was 
shown that the number of particles for PVA NCs was approximately twice than for 
the PVA NSs at all concentrations.  This can explain the increased toxicity of the 
PVA NCs in comparison to the NSs observed in the Bradford assay.  This illustrates 
the importance of taking particokinetics into consideration in the in vitro studies for 
toxicity assessment or particle uptake investigations.  For example, the influence of 
particle size on the phagocytosis by mouse peritoneal macrophages was studies 
using polystyrene particles of different sizes (Tabata and Ikada., 1988).  It was 





of 1-2 µm.  Similar studies have been carried out by Shafer et al., using 
polyalkylcyanoacrylate, polymethylmethacrylate and human serum albumin 
nanoparticles (Shafer et al., 1992).  The study claimed that nanoparticles of the 
same material were taken up to a larger extent if they were of larger diameter, which 
corroborates the findings of Tabata and Ikada (Tabata and Ikada., 1988).  The 
differences in particle uptake by particles of different sizes in these studies could be 
due to the differences in the number of particles reaching the cells.  Therefore, 
particokinetics modelling in such studies can be used to adjust the nominal doses for 
accurate predicted doses so that any change in particle uptake would reflect the 




The present work established the suitability of PVA nanoparticles as a drug delivery 
system for rifampicin.  The MTT assay revealed a negligible in vitro toxicity of PVA 
nanoparticles in J774A.1 cells, hence justifying biocompatibility of this delivery 
system.  In addition, the PVA nanocarriers were shown to increase rifampicin uptake 
substantially in comparison with the free drug.  The particokinetics model 
demonstrated the importance of predicted dose calculations in the in vitro studies. 
 
One of the reasons for the failure of anti-TB therapy is the exposure of mycobacteria 
to sub-therapeutic levels of antibiotics.  Conventional therapy by the oral and 
parenteral routes fails to deliver anti-TB drugs to AMs and granulomas harbouring 





carriers to be in contact with AMs and higher drug deliverey to these cells and lung 
lesions.  Therefore, in next Chpater PVA nanocarriers will be incorporated into an 

























Since most of the TB manifestations are observed mainly in the respiratory system, 
treatment by local delivery to the lungs by inhalation has emerged as an attractive 
alternative to oral dosing (Pandey et al., 2005).  In Chapter 4, it was demonstrated 
that encapsulating rifampicin into PVA nanocarriers increased the association of the 
drug with the macrophages.  Pulmonary delivery of the PVA carriers provides an 
opportunity to optimise the ability of AMs that harbour the mycobacterium to be 
exposed to higher doses of rifampicin.  In addition, the potential of these carriers to 
release their drug load in a sustained fashion in the lungs, the primary site of 
infection in TB, could lead to reduced doses and less frequent administration, which 
will minimise systemic toxicity of the drugs and potentially improve patient 
compliance (Pandey et al., 2005).   
 
The administration of anti-TB drugs-loaded nanoparticles by nebulisation has been 
shown to be a promising alternative to the oral delivery (Muttil et al., 2009).  Using 
nebulisation, Pandey et al., (2003) demonstrated that PLGA nanoparticle-loaded 
anti-TB drugs have been detected in the lungs 11 days post administration.  In 
addition, five doses of nanoparticles administered every 10 days shown to have the 
same anti-TB effectiveness as 46 oral daily doses (Pandey et al., 2003).  In another 
study, Zahoor et al., (2005) encapsulated rifampicin, isoniazid and ethambutol in 
alginate nanoparticles which were detectable up to 14, 10 and 14 days, respectively, 
as opposed to the fast clearance of the free drugs after 12–24 h. Nebulization of 
drug-loaded alginate nanoparticles (1 dose twice a week, 3 doses) over the course 





infected guinea pigs as 45 oral daily doses of the free drugs.  The ability of 
nebulization to administer the anti-tubercular drug-loaded nanocarriers is evident 
from the previous studies but in Chapter 3, it was demonstrated that, upon 
manufacture of the nanoparticles, rifampicin is continuously released from the 
nanocarriers.  During storage, drug release is a significant problem for nanocarriers 
as the formulation will revert to activity like a simple solution (Zhao et al., 2010a; 
Zhao et al., 2010b). 
 
Successful deposition into deep lung will localise the nanocarriers with AMs, but this 
requires the particles be large enough to avoid exhalation (Tsapis et al., 2002; Gill et 
al., 2007). The optimal particle size for achieving delivery deep into alveolar region 
has been established to be an aerodynamic diameter between 1 and 3 µm (Byron, 
1986).  Therefore the nanoparticle carrier must be formulated within large structures 
for delivery to avoid a large fraction of the inhaled nanoparticles (up to 80%) 
escaping lung deposition (Finlay et al., 1997; Heyder et al., 1986; Heyder and 
Rudolf, 1984). 
 
One way to overcome the challenges of pulmonary delivery of nanosystems is the 
use of hydrophilic microparticle vector.  If the PVA nanoparticles can be 
encapsulated into an inert microparticle of a suitable particle size it can be deposited 
in the deep lung.  Carbohydrates are widely used as carriers in dry powder 
formulations as they are approved for inhalation purposes by the Food and Drug 
Administration (Bosquillon et al., 2001).  Moreover, their non-toxicity and 








Figure 5.1.  Decomposition of microparticles into nanocarriers following their 
deposition in the lung (Makino et al., 2006). 
 
 
It was previously demonstrated that the rate of rifampicin release from the PVA 
nanocarriers was dependent on the pH of the release media.  PVA hydrolysis is 
accelerated in the presence of an acidic or alkaline catalyst.  To investigate the 
extent to which the administration of nanocarriers in a dry powder form would 
reproduce the release profiles observed when nanoparticles were delivered as a 
suspension the incorporation of a pH-modifier in the nanocarrier-containing dry 
powder formulation will be attempted. 
 
It was hypothesized that developing nanoparticle-containing microspheres, with an 
aerodynamic diameter between 1 and 5 µm, would facilitate the co-localization of 





in this chapter was to investigate the ability of microencapsulated PVA nanoparticles 
to deliver rifampicin from a dry powder inhaler.  To achieve this aim the following 
objectives were set: 
 Spray dry the PVA nanoparticles with lactose to produce microspheres of an 
inhalable aerodynamic diameter.  
 Characterize the formulations with regard to their yield, particle size, 
dissolution in aqueous solutions, drug content and morphological evaluation. 
 Investigate the nature of rifampicin release when presented to a liquid 
interface using the microparticle vector.  
 Investigate the effect of pH modifier inclusion in the dry powder formulation on 









Lactose and succinic acid were purchased from Sigma Aldrich, UK.  Other materials 




5.3.1. Preparation of nanoparticle-loaded microsphres 
Blank and rifampicin-loaded PVA nanoparticles were prepared and purified 
according to Section 3.4.1. 
 
5.3.2. Microsphere production by spray drying 
Spray drying was performed with a mini-spray drier (Buchi laboratoriums-Technik, 
Flawil, Switzerland), which operates on the principle of a nozzle spraying in a parallel 
flow (Table 5.1).   
Spray drying parameters Operational conditions 
Inlet air temperature (oC) 180 
Aspiration setting (%) 85 
Feed flow rate (ml/min) 2 
Air flow rate (l/h) 700 
Atomising air pressure (psi) 80 
 








For the preparation of rifampicin- and blank PVA nanoparticle-loaded microspheres, 
1 ml of concentrated nanosuspensions was mixed with lactose dissolved in distilled 
water (3 g in 90 ml of water) using magnetic stirring for 10 min.  The mixture volume 
was adjusted to 100 ml with additional water.  For the preparation of microspheres 
containing a pH modifier, 1g of the pH modifier (either sodium hydroxide or succinic 
acid) was dissolved in a lactose solution (2 g in 90 ml of water) by magnetic stirring 
for 10 min.  The mixture volume was then adjusted to the desired volume (100 ml) 
with additional water.  Aqueous suspensions of lactose (3 g in 100 ml) were also 
spray dried in the same conditions as controls.  The preparation spray drying feed 
stock was maintained under moderate agitation and supplied into the spray drier 
using a peristaltic pump.  The dried powders were recovered, weighed and stored at 
room temperature, protected from light, in the presence of a dessicant potassium 
pentoxide.  For process yield determination the spray-dried powders collected were 
weighed and the yield was calculated by dividing these quantities by the total mass 
in the drying feed stock for each batch. 
5.3.3. Particle size analysis 
The particle size distribution (PSD) of each sample was evaluated using a Sympatec 
Helos/Rodos laser diffraction particle-size analyzer (Sympatec Inc. Germany). 
Approximately 20 mg of powder was introduced to the dry dispersion feeder system 
using a vibratory feed tray. The dispersion pressure was set at 4.0 bar (found optimal 
to break up any loose agglomerates in the sample). The laser diffraction system, 
equipped with the appropriate lens for the sample's particle-size range was used to 
measure the PSD of the sample. The cumulative PSD and D10, D50, D90 were 





5.3.4. Particle morphology 
Microparticles were mounted on 0.5 inch aluminium stubs using double sided 
adhesive tape discs.  The samples were spatter coated operated at an electrical 
potential of 2.0 kV, a current of 20 mA and at high vacuum (0.02 Torr) for 2 min.  
This procedure resulted in a film of gold, approximately 15 to 20 nm thick, being 
deposited on the specimen.  The electron micrographs were recorded on 220 size 
Ilford FP4 film using a scanning electron microscope.  
 
 
5.3.5. Nanoparticles recovery from dry powders in aqueous medium 
A 100 mg aliquot of spray dried powder was dispersed in a bottle containing 5 ml of 
PBS (pH 7.4) under magnetic stirring at a temperature of 37 oC.  The particle size of 
released NP from each formulation was measured by PCS. 
 
5.3.6. Drug uniformity content 
Drug uniformity content for each formulation was determined by dissolving 100 mg of 
the spray dried powder in a 20 ml mixture of ethanol: water (50:50) and drug was 
quantified using HPLC (Section 3. 3. 4). 
 
5.3.7. The preparation of PVA nanoparticle-pH modifier containing powders 
Rifampicin-loaded PVA nanospheres-containing microspheres were blended with 
pH-modifier containing-microspheres at 1: 1 ratio.  The two powders were mixed for 






5.3.8. pH measurements 
Three powders were used in the experiments: (a) Rifampicin-loaded nanospheres 
containing-microspheres, (b) Rifampicin-loaded nanospheres containing-
microspheres: Sodium hydroxide-containing microspheres (1:1) and (c) Rifampicin-
loaded nanospheres containing-microspheres: Succinic acid-containing 
microspheres (1:1).  5 mg aliquot of each powder was dispersed in 2 ml of PBS (pH 
7.4) and maintained under moderate agitation.  The pH of the mixture was 
determined at 0, 6, 12 and 24h. 
 
5.3.9. Deposition characterisation 
 
A Twin Stage Impinger (TSI, Apparatus, British Pharmacopoiea 2000) was adapted 
to accommodate a filter-containing transwell in the lower chamber where particles 
with an aerodynamic diameter of less than 6.4 um were normally deposited.  A size 3 
capsule containing approximately 20 mg of powder was placed in a handheld, 
breath-activated inhaler device (Aerolizer®, Novartis, Fig. 6.2). The capsule was 
punctured, a pump was actuated to simulate an inspiration (utilizing an air flow rate 
of 30 L/min for a duration of 8 s) and the powder was deposited on different stages.  
The procedure was repeated 20 times for each formulation (n=3).  Stage 1 and stage 
2 of the impinger contain respectively 7 and 30 mL of collecting solvents 









5.3.10. Mass of powder delivered to the transwell 
 
Deposited powders were recovered from the transwell by removal of the filter 
membrane which was then placed into a glass bottle containing 1 ml of solvent 
(ethanol/water 50/50 v/v) and sonicated for 5 minutes.  Powder in the device, 
mouthpiece, stages 1 and 2 was dissolved by rinsing with fresh solvent 
(ethanol/water 50/50 v/v) and the solutions were then diluted to appropriate volumes.  
Rifampicin content on each stage was determined using HPLC.  Powder deposited 
on stage 1 corresponds to the amount deposited in the mouth and throat whereas 
powder deposited on the transwell and stage 2 corresponds to what is actually 
deposited in the lungs.  
 
 






5.3.11. Release kinetics of microencapsulated nanoparticles 
 
Four formulations were aerosolised into the TSI containing a filter-containing 
Transwell placed in the lower chamber as described above.  Deposited powders 
were recovered from the transwell by the removal of the membrane which was then 
placed into a glass bottle containing 1 ml of phosphate buffer and maintained in 
moderate agitation at 37 oC.  At 0 and 24 h 0.5 ml samples were withdrawn from the 
suspensions.  The nanoparticles were separated from the dispersing medium by 
ultrafiltration/centrifugation technique using 0.5 ml centrifugal concentrators with 
MWCF of 100 kDA (Amicon Ultra 0.5ml) at 3000×g for 5 min. The drug content in the 
nanoparticles and the dispersing medium were analysed by HPLC.  Drug remaining 
in the nanoparticles was calculated after 24 h (n = 3) (equation 6.1). 
       
    
  
        (6.1) 
Where Wd is the percentage mass of the drug remaining in the nanoparticles; Mt24  is 
the mass of drug in the nanoparticles at t24 and M0  is the mass of drug in the 
nanoparticles at t0. 
 
 
5.3.12. Data analysis and statistics 
 
All data was expressed as mean ± standard deviation (S.D.)  Statistical analysis was 
performed in SPSS, version 16.0, using either student t-test or an analysis of 







5.4.1. Spray dried microsphere characteristics: 
Incorporating blank or rifampicin-loaded PVA nanocarriers into microspheres did not 
have any effect on particle size (Table 5.2).  In contrast, the incorporation of a pH 
modifier resulted in a significant increase in particle size (p < 0.05).  The recovery 
yields ranged from 43.7 to 54.8 % for the nanocarrier-conatining microspheres.  The 
recovery yields were much lower for the pH modifier-containing microspheres 
resulting in 32.3 ± 8.41 and 35.9 ± 4.25 % yields for NaOH-containing microspheres 





Particle size (µm)  
Yield (%) X10 X50 X90 
B-NS-MS 0.45 ± 0.023 2.28 ± 0.015 3.84 ± 0.006 46.3 ± 5.23 
Rif-NS-MS 0.32 ± 0.015 1.86 ± 0.053 3.61 ± 0.176 43.7 ± 4.78 
B-NC-MS 0.36 ± 0.032 2.02 ± 0.049 3.59 ± 0.015 54.8 ± 7.36 
Rif-NC-MS 0.33 ± 0.021 1.82 ± 0.114 3.36 ± 0.131 52.6 ± 8.57 
NaOH-MS 0.57 ± 0.02 2.65 ± 0.036 6.90 ± 0.064 32.3 ± 8.41 
Succ-MS 0.61 ± 0.04 3.42 ± 0.207 23.75 ± 1.551 35.9 ± 4.25 
 
Table 5.2.  Particle size of the different spray dried powders: B-NS-MS (blank 
nanosphere-microspheres; Rif-NS-MS (rifampicin-loaded nanosphere-
microspheres); B-NC-MS (blank nanocapsules microspheres;  rifampicin-loaded 
nanocapsules microspheres (Rif-NC-MS);  NaOH-MS (blank NaOH-microspheres)  
and Succ-MS ( blank succinic acid-microspheres) using laser diffraction, yield of 





SEM micrographs indicated that the NS- and NC-containing microspheres were 
spherical in shape with smooth surfaces (Figures 5.3A and 5.3B).  The pH-modifier-
containing microspheres had a rough surface and appeared to be a little aggregated.  
The NC-containing powder was very sticky and the presence of big agglomerates of 
paricles in the powder can be seen (Figure 5.3B).   
 
5.4.2. Drug uniformity content and nanoparticles recovery from dry powders in 
aqueous medium 
 
The amount of nanoparticles encapsulated in the microspheres was similar for PVA 
nanospheres and PVA nanocapsules, approximately 820 µg of nanoparticles per 100 
mg of powder (Table 5.3).  However, Drug content of rifampicin-nanospheres-
containing powders was almost three times higher than the rifampicin-nanocapsules-
containing powders.  The spray dried microspheres dissolved instantly when 
dispersed in aqueous solution.  The mean particle size of the nanoparticles in the 
resultant suspensions was measured and found to be increased for both 



































215.7 ± 5.8 
 
265.3 ± 21.2 
 
187.1 ± 19.4 
 
816.9 ± 84.7 
Rif-NC-MS 142.9 ± 7.2 231.8 ± 17.7 66.9 ± 4.3 822.1 ± 52.5 
 
Table 5.3.  Nanoparticle size before spray drying and after microsphere dissolution 
in aqueous solutions and drug uniformity content of rifampicin-nanosphere-loaded 
microspheres (Rif-NS-MS) and rifampicin-nanocapsules-loaded microspheres (Rif-
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Figure 5.3. Representative scanning electon micrographs of the spray dried 
formulations: (A) PVA nanosphere-microspheres, (B) PVA nanocapsule 










5.4.3. pH monitoring of powders at phosphate buffer pH 7.4 
The incorporation of a pH modifier in the microspheres and blending it with 
nanoparticle-containing microsphres had a significant effect on the pH of the 
incubation media (p < 0.05).  For sodium hydroxide-containing microspheres, the pH 
was constantly higher than 10 over the 24 h period.  In contrast, the pH of the 
suspension was constantly lower than 5 when the nanospheres-containing powders 




Figure 5.4.  pH values of the suspension of Rif-NS-MS (diamond), Rif-NS-MS: 
NaOH-MS (1:1) (square) and Rif-NS-MS: Succinic acid-NS-MS (1: 1) (Triangle).  



















5.4.4. The deposition of the nanocomposite particles 
 
The recovery of formulations after aerosolisation was high (between 80 and 101 %) 
for all formulations (Table 5.4).  NS-containing powders (R-NS-MS) had a higher 
deposition than the nanocapsule-containing powders (R-NC-MS) (Figure 5.5).  The 
percentages of powder depositing on the transwell and stage 2 were 5.6 and 22.5 %, 
respectively, for R-NS-MS, and 0.7 and 6.2 % for R-NC-MS.  There was no effect on 
the deposition pattern when the R-NS-MS were blended with NaOH-MS.  However, 
mixing R-NS-MS with succinic acid-microspheres the percentage of powder 





Table 5.4.  The amount of rifampicin in the delivered dose, the amount of rifampicin 
on different stages of the TSI after deposition of the different spray-dried powders 
and % recovery of rifampicin-loaded nanosphere-microspheres (Rif-NS-MS); 
rifampicin-loaded nanospheres-microspheres: NaOH-microspheres (Rif-NS-MS: 
NaOH-MS); rifampicin-loaded nanospheres: succinic acid-microspheres (Rif-NSMS: 
Succ-MS) and rifampicin-loaded nanocapsules microspheres (Rif-NC-MS).  Data 





Delivered dose (µg) Transwell Stage 2 Stage 1 Device Mouthpiece Recovery
Rif-NS-MS 730.3 ± 71.4 40.95 ± 5.29 164.8 ± 19.8 328.9 ± 8.4 160.6 ± 10.8 23.6 ± 1.4 98.7 ±  4.6
Rif-NS-MS: NaOH-MS 323.9 ± 18.5 23.97 ± 4.29    79.1 ± 09.3 156.9 ± 9.5 59.1 ± 12.5 10.5 ± 0.9 101.7 ± 0.7
Rif-NC-MS: Succ-MS 293.6 ± 07.6 0.27 ± 0.04     18.2 ± 03.9 202.1± 12.8 10.03 ± 1.5 6.8 ± 3.3 80.9 ± 0.8








Figure 5.5.  Percentage of powder deposited on different stages of the TSI for four 
different formulations: rifampicin-loaded nanosphere-microspheres (Rif-NS-MS); 
rifampicin-loaded nanospheres-microspheres: NaOH-microspheres (Rif-NS-MS: 
NaOH-MS); rifampicin-loaded nanospheres: succinic acid-microspheres (Rif-NSMS: 
Succ-MS) and rifampicin-loaded nanocapsules microspheres (Rif-NC-MS).  Data 
represent mean ± SD. 
 
5.4.5. Release kinetics of microencapsulated nanoparticles 
As it can be seen from figure 5.6, the amounts of rifampicin remaining in the 
nanoparticles were approximately 85 and 67 %, for nanospheres and nanocapsules, 
respectively.  Once the pH modifier powder was mixed with the R-NS-MS, the 
release of the drug to the aqueous phase was enhanced.  The amount of drug 
remaining in the particles decreased to 64 and 49 %, after the introduction of sodium 




































Figure 5.6.  The percentage of drug remaining in the nanoparticles after 24 h 
incubation of rifampicin-loaded nanosphere-microspheres (NS); rifampicin-loaded 
nanospheres-microspheres: NaOH-microspheres (NS-NaOH); rifampicin-loaded 
nanospheres: succinic acid-microspheres (NS-Succ) and rifampicin-loaded 





















































It was previously demonstrated that rifampicin was prone to continuous diffusion out 
the PVA nanoparticles upon manufacture.  The incorporation of nanoparticles in a 
dry powder formulation would increase the shelf life of the formulation during storage 
and minimize drug diffusion out of the particles before administration.  Therefore, in 
this chapter the feasibility of developing carrier particles to deliver PVA nanocarriers 
to the lower airways was investigated.  
 
Spray drying was shown to be suitable as a mean to load PVA nanoparticles into a 
lactose microparticle vector.  A carbohydrate was selected for the micropaticle matrix 
as it is approved by the Food and Drug Administration (FDA) for pulmonary delivery, 
and widely applied in pulmonary formulations (Bosquillon et al., 2001b).  The 
microspheres produced in this work had a diameter of 2 to 4 µm which was 
considered to be suitable for delivery to the lower airways (Byron, 1986).  The yield 
of PVA nanoparticle-containing microspheres during manufacture ranged from 43 
and 55 %.  Similar yield values have been reported for spray drying chitosan 
nanoparticles with lactose/mannitol (Grenha et al., 2005).  SEM micrographs 
revealed that nanoparticle-containing microspheres were spherical in shape and had 
a smooth surface in comparison with the blank lactose microspheres and the pH 
modifier-containing microsphres.  Grenha et al., (2005) observed that upon the 
incorporation of chitosan nanoparticles, the resulting mannitol microspheres showed 
more defined limits and spherical shape as the nanoparticles amount increased with 





nanoparticles as a solid structure contribute to the enhancement of microspheres 
morphology, once these can grow around a solid body (Grenha et al., 2005).  The 
PVA nanocapsule-containing microspheres were shown to have a high tendency to 
agglomerate.  This could be attributed to the presence of phospholipids in the 
formulation.  The agglomeration of the primary particles and the adhesiveness of 
agglomerates can be explained by the degradation of the nanocapsules coating the 
microsphere surface (Tewa-Tagne et al., 2006). 
 
Drug uniformity content data show that the encapsulation efficiency for the PVA 
nanospheres in the microspheres was significantly higher than the PVA 
nanocapsules (p < 0.05).  This could be explained by the loss of the nanocapsules 
during the spray drying procedure.  Tewa-Tagne et al., (2006) demonstrated that 
with insufficient concentration of adjuvant spray drying nanocapsules led to strong 
adhesive products onto the apparatus walls (Tewa-Tagne et al., 2006).  In this work, 
lactose concentration was not sufficient to interact with all nanocapsules present in 
the feed.  Therefore, the excess of nanocapsules adhered to the cyclone walls. 
.   
 
The ability of the obtained dry powders to release the nanoparticles following 
incubation in phosphate buffer (pH 7.4) was investigated.  This experimental set up 
was chosen as It was assumed that the airway surface liquid has a pH of 
approximately 7, close to that of the interstitial fluid and plasma (Walters, 2002).  We 
observed that after incubating the powders in the aqueous medium under low stirring 





the slight enlargement of the nanoparticles they remain in the nano-range and thus 
retained the capacity to control drug release effectively.  The enlargement of 
particles size after spray-drying was also found by Sham et al. (2004) for powders 
prepared with lactose and gelatin nanoparticles and the effect was attributed to 
eventual changes in conformation due to the thermal conditions of the spray-drying 
process (Sham et al., 2004). 
 
A twin-stage impinger was adapted to accommodate a transwel in the lower 
chamber where particles with an aerodynamic diameter of less than 6.4 um are 
normally deposited.  The amount of powder depositing on the transwell and stage 2 
was significantly lower for the PVA nanocapsules-containing microspheres than the 
PVA nanospheres-containing microspheres (p < 0.05).  This could be due to the 
surface active properties of the nanocapsule which induced agglomeration of 
particles during powder aerosolisation (French et al., 1996; Timsina et al., 1994).   
 
 
The release of rifampicin from the PVA nanocarriers is shown to be siginificantly 
enhanced when particles are incubated in basic or acidic media (Chapter 3).  In this 
chapter, there was an attempt to blend the PVA nanosphere-containing 
microspheres with pH-modifier-containing nanospheres.  The objective was to 
investigate the extent to which the administration of nanocarriers in a dry powder 
form would reproduce the release profiles observed when nanoparticles were 
delivered as a suspension.  The introduction of sodium hydroxide and succinic acid 





nanocarriers.  The pattern correlated well with the data obtained when the 
nanoparticles were presented as suspensions.  The difference in the values reported 
in the two studies could be due the differences in the experimental set up and the 
lack of the buffering effect in this experiment. 
 
In summary, the present study demonstrates that incorporation of PVA nanoparticles 
into respirable carrier particles is possible.  The spray-dried powders had a suitable 
size and shape for airway deposition.  After reaching alveolar regions, the carrier is 
expected to dissolve instantly in the alveolar lining fluid (pH 7.4) releasing the 
nanoparticles.  Blending the PVA nanosphere-containing microspheres with pH-
modifier-containing microspheres had a pronounced effect on the release of the drug 
from the PVA particles.  This delivery platform opens up a wide of treatment 
applications of pulmonary and possibly systemic diseases using targerted delivery 

























Despite the availability of potentially curative pharmacotherapies, TB remains the 
leading cause of preventable deaths (WHO, 2011).  For new cases of drug 
susceptible TB, the most effective therapeutic regimen requires 6 months of 
treatment with first-line drugs (a combination of rifampicin, isoniazid, ethambutol and 
pyrazinamide for 2 months, followed by a 4-month continuation phase of rifampicin 
and isoniazid) (BNF, 2011).  Despite its high efficacy, with cure rates of around 90 % 
in HIV-negative patients, the regimen is far from ideal.  The long duration of therapy 
and the associated side effects can hamper patient lifestyle and induces patient non-
compliance, treatment failure and development of drug-resistant strains (Chan and 
Iseman, 2008). 
Mycobacterial strains exhibiting resistance to one or more drugs are arising at an 
alarming rate, requiring the incorporation of more drugs in the increasingly complex 
combination therapy.  The current treatment of multi-drug resistant TB (MDR-TB) 
comprises of the administration of pyrazinamide simultaneously with second-line 
drugs such as ethionamide, prothionamide, cycloserine, capreomycin, p-
aminosalicylic acid or fluoroquinolones. These second-line drugs are more toxic, 
more expensive and less active than first-line agents. Also, prolonged treatment (up 
to 24 months) is required in order to assure therapeutic effectiveness (Smith, 2003).  
In this context, low patient compliance and adherence to the administration regimens 
become crucial drawbacks of the pharmacotherapy, leading to increased TB 
mortality. Therefore, novel and effective anti-TB drugs and delivery systems are 
urgently required to replace or supplement the current therapies with the aims of 






For more than 40 years, not a single new drug has been developed and licensed for 
the treatment of TB.  The emergence of MDR and extensively drug-resistant TB 
(XDR-TB) has spurred interest in the development of new drugs with different modes 
of action.  At present there is a coordinated portfolio of promising new compounds on 
the horizon, some of which have the potential to become the cornerstone drugs of 
TB treatment in the future.  There are 10 new compounds under clinical investigation 
(WHO, 2011).  The status of the pipeline for new anti-TB drugs is illustrated in table 
6.1.  
Two of the Phase III trials are evaluating 4-month regimens (in which a 
ﬂuoroquinolone, gatiﬂoxacin or moxiﬂoxacin, is used in place of ethambutol or 
isoniazid) for the treatment of drug-susceptible TB.  The third Phase III trial is 
evaluating the use of rifapentine (a rifamycin that has a longer half-life than 
rifampicin) as part of a 4-month regimen. The use of rifapentine in combination with 
isoniazid for a shorter (3 months) treatment of latent TB infection is also being 
evaluated.  
Of the compounds in Phase II trials, two are in the advanced stages of being tested 
for the treatment of MDRTB. These are TMC-207 (bedaquiline) and OPC-67683 
(delamanid). Both compounds have been evaluated in Phase IIb trials in newly-
diagnosed MDR-TB patients, in which either the investigational drug or a placebo 
were added to an optimized background regimen.  Other compounds in Phase II 
trials include linezolid, which is being tested for the treatment of extensively drug-
resistant TB (XDR-TB) at a dose of 600 mg (in the Republic of Korea) and at a dose 
of 300 mg for the treatment of MDR-TB (in South Africa) ; PNU-100480 (a close 





November 2010, the ﬁrst clinical trial of a novel TB drug regimen (NC001), 
investigating the bactericidal activity of a three-drug combination of PA-824, 
moxiﬂoxacin and pyrazinamide was initiated.  
These major advances in TB drug development mean that multiple trials will be 
needed in various high-burden countries.  This presents several challenges.  Trials 
are lengthy and costly since patients need to be followed for an extended period of 
time after completing treatment.  New drugs have to be tested in specified drug 
combinations with current and newly re-purposed drugs.  Moreover, researchers will 
be always faced with some of the old challenges of the conventional therapy.  The 
inability of the new drugs to reach the bacilli in alveolar macrophages and lung 
granulomas can lead to the recurrence of the infection and consequently, in the long 
term, development of resistance to the new agents.  Strategies allowing more 
efficient delivery of the anti-TB drugs to the infection reservoirs will be needed.  
Therefore it is not guaranteed to have a new drug in clinical use in the near future.  
On the other hand, first generation anti-TB drugs, such as rifampicin, are still highly 
effective.  Overcoming the main pharmaceutical drawbacks of the conventional 
therapeutic agents to improve their effectiveness as well as to enhance compliance 
and adherence represents an attractive strategy and remains the main goal of the 






Figure 6.1.  The development pipeline for new drugs (WHO, 2011). 
 
Despite its association with a number of issues, rifampicin is still considered to be a 
powerful anti-tubercular agent.  Rifampicin has poor and variable bioavailability 
because of its poor solubility, acid decomposition, variability in absorption and 
metabolism.  It is associated with a number of side effects and known to cause 
severe liver damage when combined with isoniazid.  It reduces the concentrations of 
anti-retroviral drugs used in AIDS by inducing the metabolising enzyme cytochrome 
P450.  Another problem is attaining an effective concentration of rifampicin in the 
infected organ, the lungs.  After oral administration of rifampicin, the concentration of 
rifampicin reaching the lungs is insufficient to provide anti-bacterial effects on the 
bacilli located in lung lesions and alveolar macrophages.  This has been related the 
drug instability and its interaction with isoniazid after oral administration.  
Encapsulating rifampicin into a carrier delivery system that can release the drug in a 
controlled manner at therapeutic concentration over a period of time can solve most 













































bioavailability, side effects and drug interactions) as well as improve patient 
compliance in terms of reducing dosing frequency.  The ability of these carriers to 
deliver the drug directly to the lungs may allow therapeutic concentrations to 
penetrate effectively into lung lesions and eradicate the resident mycobacteria in 
alveolar macrophages. 
In this context, nanotechnology appears be one of the promising approaches for the 
development of more effective drug delivery systems for the treatment of TB.  Over 
the past 3 decades, the potential for replacing the administration of therapeutic 
agents in the free from with an approach of encapsulating them into nanoparticles 
has been extensively investigated.  Many advantages of nanoparticle-based drug 
delivery have been recognized (Emerich et al., 2007; Groneberg et al., 2006).  It 
improves the solubility of poorly water-soluble drugs, releases drugs at a sustained 
rate or in an environmentally responsive manner and thus lowers the frequency of 
administration, delivers drugs in a targeted manner to minimize systemic side 
effects, and can deliver two or more drugs simultaneously for combination therapy to 
generate a synergistic effect and suppress drug resistance. Currently, more than 20 
nanoparticle therapeutics are in clinical use (Table 6.1), validating the ability of 
nanoparticles to improve the therapeutic index of drugs. In addition to the already 
approved nanoparticles, numerous other nanoparticle platforms are currently under 









Table 6. 1.  Clinically approved nanoparticle-based therapeutics (adapted from 






With regard to TB, some of the striking data have come from a number of in vivo 
studies using anti-TB drugs encapsulated into polymeric nanoparticles in animal 
models infected with M. Tuberulosis.  Most of these studies used PLGA to 
encapsulate rifampicin, isoniazid or both into the nanocarriers (gelprina et al., 2005)  
Taking Sharma and colleagues study as an example, only three oral applications of 
the PLGA nanoparticle-loaded anti-TB drugs gave the same therapeutic protection 
against M. TB in guinea pigs as 45 daily doses of the free antibiotics (Sharma et al., 
2004).  Thus the nano-encapsulation of anti-TB drugs has the potential to 
substantialy reduce the dosing frequency for anti-TB drugs, leading to enhanced 
patient compliance, improved treatment success rate and reduced drug resistance 
incidence.  Therefore, the aim of this project was to encapsulate rifampicin into new 
polymeric nanoparticles that can deliver and release the therapeutic agent in a 
controlled manner in the lungs, as well as have the potential to target the bacilli 
residing in alveolar macrophages and lung lesions. 
Poly (vinyl alcohol) (PVA) is a synthetic crystalline polymer formed by the full or 
partial hydrolysis of poly (vinyl acetate) PVAc.  Partially hydrolysed grades have both 
hydrophobic and hydrophilic character due to the presence of vinyl acetate and vinyl 
alcohol groups, respectively.  The aqueous solubility of partially hydrolysed PVA is 
dependent on the degree of hydrolysis, which determines the ability of the PVA to 
form hydrogen bonds with water.  The hydrophilic grades of PVA (70-95 % 
hydrolysed) have been used widely as coating and stabilising agents in 
pharmaceutical products, ranging from oral to topical formulations.  However, the 
potential of using this amphiphilic polymer as drug carrier has never been 






Using solvent displacement method, two types of nanoparticles were employed in 
this study: nanospheres (NS) and nanocapsules (NC).  In NS, the therapeutic agent 
was shown to be entrapped in the hydrophobic polymer matrix and surrounded by 
hydrophilic stabilizing polymer. In NC, the drug is dissolved in the oily core (benzoyl 
benzoate) surrounded by thin hydrophobic PVA layer and stabilized by poloxamer 
188 surfactant (Figure 6.2) (Fessi et al., 1989). The aqueous suspension of both NS 
and NC were physically stable.  The absence of surface charge (neutral zeta 
potential value) indicated that both systems were stabilised by steric repulsion 
















In this study, a hydrophobic grade (40 % hydrolysed) of PVA was used successfully 
for the encapsulation of rifampicin into nanocarriers.  Despite, the hydrophobic 
nature of PVA, rifampicin had higher affinity to the aqueous phase than to the 
polymer.  This was also observed by Esmaeili et al. (2005) when they attempted to 
encapsulate rifampicin into PLGA nanoparticles, although higher encapsulation 
efficiency was achieved in this work than the one reported by Esmaili et al., (2005).  
The diffusion to the continuous phase was decreased by employing pH 4.8 in this 
aqueous phase.  In Chapter 2, it was demonstrated that rifampicin degrades rapidly 
in aqueous solutions and that encapsulating it into PVA nanocarriers would protect 
the drug after its administration, and increase its effectiveness. 
 
 
A centrifugal filtration technique was employed to assess the drug release in situ 
from nanoparticles. The release characteristic was shown to be dependant on the pH 
of the dissolution medium.  At pH 7.4 the release rate was slow for both nanoparticle 
systems.  In contrast, higher release rates were observed in pH 4.2 and pH 10.  This 
was due the accelerated erosion of the polymer in acidic and alkaline media.  The 
mechanism of polymer erosion is postulated to involve the adsorption of the alkali or 
the acid catalyst onto the free hydroxyl groups resulting in the hydrolysis of the 
acetate groups of the polymer, also known as alcoholysis.  This makes this polymer 
an interesting material for drug delivery purposes and it would be interesting to 
manufacture nanoparticles using different grades of the polymer to assess the 





PVA nanocarriers interaction with J774A.1 cells was investigated in Chapter 4.  It 
was shown that the nanoencapsulation of rifampicin not only reduced the toxicity of 
the drug to the cells but but also increased the association of the drug with these 
macrophages compared to free drug.  This shows that the encapsulation delivers 
rifampicin into the cells using an additional cellular internalization process, 
presumably phagocytosis or endocytocis (Vauthier et al., 2003).  The in vitro 
particokinetics study provided us with some vital information on the system.  It 
showed that delivered doses of PVA NSs and NCs to the cells during the experiment 
were significantly different.  Therefore, nominal dose cannot be used to compare the 
two systems in terms of efficacy and toxicity.   
 
Administration of anti-TB drugs by the pulmonary route for management of TB may 
lead to therapeutically effective drug concentrations in regions of the lungs 
containing large burdens of bacteria and reduce chances of infection reccurence and 
drug resistance.   Nanoparticles have been previously delivered to the lungs by 
nebulisation of colloidal solutions (Kawashima et al., 1999; Vaughn et al., 2006; 
Yamamoto et al., 2005).  However, nanoparticles prepared and stored in an aqueous 
medium will constantly release the drug to the outer phase prior administration, 
either by diffusion through the polymer barriers or by the erosion of the polymer over 
time.  Suspension stability is another concern owing to particle-particle interaction, 
which could lead to poor functionality of the nebulizer.  One way of solving the 







Spray drying has been reported to be a successful method for incorporating 
nanoparticles into dry powder.  Drying nanoparticles and delivering as a dry powder 
is not easily achieved given that nanoparticles aggregate excessively in the dry state 
(Saez et al., 2000; Wendorf et al., 2006).  Alternatively, nanoparticles delivered in 
unaggregated dry particle form do not deposit efficiently in the lungs and are 
generally exhaled from the lungs owing to their low inertia (Heyder et al., 1984).  To 
overcome these issues, nanosuspensions were spray dried in the presence of a 
carbohydrate (lactose) to obtain microspheres that are physically stable in the 
powder form and have an appropriate size to deposit in the lungs.   
 
The nanoparticle containing-microspheres produced were spherical in shape with 
diameters of 2 to 4 µm.  The PVA NC-containing microspheres were shown to have 
a high tendency to agglomerate.  The degradation of the nanocapsules coating the 
microsphere surface was responsible for the agglomeration of the primary NC and 
the adhesiveness of agglomerates (Tewa-Tagne et al., 2006).  There was loss of the 
NCs during the spray drying procedure due to insufficient lactose concentration 
interacting with all NCs present in the feed.  This resulted in low NC encapsulation 
efficiency in the microspheres compared to the NSs.  Therefore more work needs to 
be carried out to optimise this formulation by investigating the effect of different NC: 
lactose ratios on the encapsulation of these NCs during the spray drying procedure.   
Both PVA nanocarriers were instantly released from the microspheres after 
incubation in an aqueous medium.  However, there was an enlargement in particle 
size.  This was attributed to changes in conformation due to the thermal conditions of 





accommodate a Transwell in the lower chamber where particles with an 
aerodynamic diameter of less than 6.4 µm deposit.  The amount of powder 
depositing on the transwell and stage 2 was significantly higher for the PVA NS-
containing microspheres than the PVA NC-containing microspheres (p < 0.05).  The 
poor aerosolisation properties of the NC--containing powders is a result of particle 
agglomeration (French et al., 1996; Timsina et al., 1994).  The introduction of a pH 
modifier (sodium hydroxide or succinic acid) to the powder successfully enhanced 
the release of the drug from the nanocarriers.  The pattern correlated well with the 
data obtained when the nanoparticles were presented as suspensions.  It was 
postulated the pH modifier, once dissolved, acts as a catalyst for PVA hydrolysis.  
The accelerated erosion of the polymer increased the amount of rifampicin released 
from PVA NS.  Although the microencapsulated nanoparticle systems require further 
optimisation, the current study showed the potential of encapsulating PVA 
nanocarriers into a rapidly-dissolving carrier as a pulmonary delivery system.  
Encouraging results have been obtained with the PVA NS powders and PVA NS-
sodium hydroxide powders in terms of drug release, flowability and aerolisation.   
 
Administering rifampicin-loaded nanocarriers by the pulmonary route to the lungs 
may allow therapeutic concentrations of drug to penetrate effectively into lung 
lesions and alveolar macrophages harbouring mycobacteria.  The approximate 
inhaled dose of rifampicin-loaded NS powder required for therapeutic use was 
calculated based on previous in vivo studies administering rifampicin-loaded 
nanoparticles by inhalation to animals (Pandey et al. 2003; Khuller et al., 2005; 





of rifampicin-loaded nanoparticles would result in a 13- to 19-fold increase in the 
bioavailability of the drug compared to the oral delivery of free drug.  Taking that into 
account, a theoretical dose of rifampicin was calculated for use in this project.  A 
reduced aerosol dose (by a factor of 13-19) would theoretically result in the same 
bioavailability as a 600mg delivered orally. 
 
             
         
 
 
     
 
      
 
 
where x was taken as 15 
 
Considering the drug content capacity of the NS-containing powders produced in this 
project is approximately 200 µg of drug per 100 mg of powder.  Thus 20 g of powder 
will be required to deliver 40 mg of active agent and would theoretically result in the 
same bioavailability as a dose of 600 mg orally every day.  Delivering 20 g of powder 
is not practically possible.  One way of improving dosimetry is by spray drying the 
nanoparticles in the absence of the carrier.  This would produce large hollow or 
porous structures known as porous nanoparticle-aggregate paticles (PNAP) (Tsapsis 
et al., 2002).  Considering that the produced powders would constistute rifampicin-
loaded NSs only, the drug content capacity would be approximately 25 mg of drug 
per 100 mg of powder and the delivered dose required will be reduced from 20 g to 
approximately 160 mg of nanoparticle-loaded powders.   
A different approach would be the local delivery of these nanoparticle-based systems 
as an adjunct to the oral conventional therapy (Figure 6.3C).  Current clinical studies 





However, firmly established WHO protocols for treatment of TB worldwide by 
predefined dosage forms of oral drugs, and the large current market for fixed-dose 
combinations (FDC) means that realigning policies and the manufacturing industry 
towards altered dosage forms would be difficult and slow. Addition of a drug such as 
rifampicin in an inhaled formulation would make sense under such a scenario (Figure 
6.3B).  This has the potential to enhance local concentration in the lung, increase 
efficacy as well as allowing a reduction in the oral dose, dosing frequency and the 
duration of therapy. This may ultimately lead to less severe side effects, improved 
patient compliance and reduce the incidence of drug resistant strains of TB. 
It is estimated that among the approximately 2 billion persons throughout the world 
with latent TB, between 100 and 200 million will develop active disease during their 
lifetimes. In North America and several other low-incidence countries, isoniazid has 
been used for the treatment of latent TB in persons at greatest risk of disease 
progression. Isoniazid has also been shown to be effective in persons with TB and 
HIV co-infection and has recently been recommended by WHO for such persons 
(WHO, 2011).  The pulmonary delivery of a nanoparticle-based formulation as a 
prophylactic treatment in high risk patients would be benefitial. However, inhaled 
therapy will need to fit in with existing National TB programmes, and with initiatives 
such as the Directly Observed Treatment Short course (DOTS) programme.  
Increased costs, together with the need for strict control of infection precautions to 
prevent device-associated cross-infections and/or risk to health personnel, may limit 
the extent to which such technologies come to be widely available, particularly in 
developing countries.  The large-scale production of a safe and effective 





affordable cost will be the fundamental and decisive obstacle which will need to be 
overcome before contemplating human trials. However, the rationale behind inhaled 
anti-TB therapy is persuasive. Hopefully, current and future research efforts will 
eventually result in this concept from the bench to the bedside. 
 
 
Figure 6.3.  Schematic representation of drug distribution in the lungs and body 
when administered by (A) Orally, more drug in the systemic circulation compared to 
lungs, (B) Inhalation, more drug in the lung compared to systemic circulation, (C) 
Combined oral and inhalation, drug equilibrium in the lungs and the systemic 
circulation (color intensity qualitative indicator). 
 
 
There are a number of areas in which further work is required in the future for the 
optimisation and the in vitro assessment of the developed nanoparticle-based 
delivery systems.  The compatibility and the suitability of the PVA polymer as an 
excipient for pulmonary delivery have to be investigated further.  It would also be 
interesting to employ different grades of this PVA for the encapsulation of the drug 
and assess the effect of degree of hydrolysis and molecular weight of the polymer on 





For the uptake experiments, a thorough investigation of the effect of different 
parameters on the uptake of these nanocarriers by macrophages would provide us 
with more information on the mechanism of cell-particle interaction.  Surface 
modification would also be an interesting aspect to explore.  Particokinetics 
modelling can be used to adjust the nominal doses for accurate predicted doses in 
such studies so that any change in particle uptake would reflect the effect of the 
variable under investigation. 
With regard to the nanoparticle-containing microspheres, the effect of incorporating a 
pH-modifier into NC-containing powders was not investigated fully to time 
constraints.  More work is required to optimise both formulations in terms of spray 
drying parameters, nanoparticle:lactose ratios, nanoparticle:pH modifier ratio.  It 
would also be necessary to carry out an aerodynamic assessment of the 
nanoparticle-containing powders using an andersson cascade impactor (ACI) or a 
new generation impactor (NGI) to determine fine particle fraction (FPF) 
Despite the fact that so much future work is required to optimise the nanoparticle-
based formulations, the results obtained in this project are very promising.  The 
present study demonstrated the utility of PVA as a carrier for delivering therapeutic 
agents.  The pH-dependant degradation of PVA makes it an interesting excipient for 
drug delivey purposes.  The PVA nanocarriers were shown to target the drug to 
macrophages compared to the free form.  Moreover, the successful incorporation of 
PVA nanoparticles into respirable carrier particles, with suitable size and shape for 
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Despite the fact that the pathophysiology of TB is very complex, the work in this 
thesis demonstrated that the simplified hypothetical scenario in figure 6.4 is 
feasible.  The manufactured PVA NS-containing microsheres can be delivered to 
the lungs.  After reaching alveolar regions, the carrier is expected to dissolve 
instantly in the alveolar lining fluid releasing the nanoparticles, which can be 
taken up readily by the alveolar macrophages harbouring the bacteria.  Once 
inside the acidic phagolysosome, the polymer is hydrolysed releasing the drug.  
Alternatively, the drug release at the epithelial surface can be induced by 
incorporating a pH modifier into these formulations to control the erosion of these 
nanocarriers.  This delivery platform opens up a variety of treatment applications 
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